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ABSTRACT 
 
The complement system, a major component of the innate immunity, is critical 
for combating microbial infections. It can be activated by three distinct pathways: the 
classical pathway, the lectin pathway and the alternative pathway. Activation of the 
complement system results in opsonization of pathogens, recruitment of phagocytes, and 
lysis of bacterial cells. However, successful pathogenic bacteria have evolved strategies 
to manipulate the complement system, aiming to tip the balance in favor of the bacteria. 
Staphylococcus aureus is an important human pathogen causing more deaths than that of 
HIV in the United States. It can cause diseases ranging from minor skin infections to life 
threatening diseases. While most complement evasion molecules from S. aureus are 
secreted proteins and are well characterized, little is known about the effect of surface-
anchored S. aureus proteins on complement activity. This study aims to bridge this gap 
and investigate the role of S.aureus surface proteins in complement evasion.   
S. aureus expresses different kinds of MSCRAMMs (microbial surface 
components recognizing adhesive matrix molecules) that interact with host extracellular 
matrix (ECM) proteins. My studies mainly focus on collagen-binding MSCRAMM Cna 
and fibrinogen-binding MSCRAMM Bbp/SdrE using the hemolysis and the C4b 
deposition ELISA-type assay to analyze complement activation and a serial biochemical 
and immunological approaches such as ELISA, biacore and IP assays to investigate the 
binding and inhibition mechanisms.  
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I found that Cna specifically interacts with the collagen-like domain of C1q. This 
binding disturbs C1 complex assembly and causes decrease in C1 binding to the immune 
complex. Moreover, animal studies revealed that C1q knockout mice are resistant to 
Cna-expressing S.aureus infections and have much less bacterial burdens in liver, 
compared to that of wild type mice, suggesting that this interaction enhances S.aureus 
infection and dissemination. Furthermore, my study also revealed that Bbp/SdrE blocks 
all three complement pathways and the binding of Bbp to C3c fragment of C3b blocks 
the formation of the AP C3 convertase by interfering with the cleavage of factor B.   
In summary, I reported that several MSCRAMMs from S.aureus not only bind to 
ECM proteins, but are also complement inhibitors that would benefit S.aureus 
infections. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW
*
 
 
Recognition of bacterial infection by innate immunity 
The immune response consists of two aspects: innate immunity and adaptive 
immunity. The innate immunity is the first line of defense, which is critical for sensing 
and killing pathogenic bacteria at early stage (Mogensen, 2009). It contains soluble 
molecules, as well as various immune cells, such as macrophages, neutrophils, natural 
killer cells, dendritic cells, all of which express a group of surface receptors or cytosolic 
receptors known as germline-encoded pattern recognition receptors (PPRs). PPRs 
interact with pathogen-associated molecular patterns (PAMPs), resulting in the release of 
proinflammatory and anti-pathogen cytokines via the activation of NF-κB, IFN-I or 
other signaling pathways (Beutler & Rietschel, 2003). The innate immune soluble 
molecules include antimicrobial peptides, which have direct antimicrobial activity or 
immunemodulatory functions (Ganz, 2003), and heat-sensitive complement components 
in blood, which identify invading microbes and kill them (Gasque, 2004).  
 
___________ 
*Part of this chapter is reprinted with permission from “Collagen-binding microbial 
surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-
positive bacteria inhibit complement activation via the classical pathway” by Kang M, 
Ko YP, Liang X, Ross CL, Liu Q, Murray BE, Höök M., 2013. The Journal of 
Biological Chemistry, 288, 20520-20531, Copyright [2013] by American Society for 
Biochemistry and Molecular Biology. 
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Figure 1 Recognition of PAMPs from pathogens by 
PRRs(Mogensen, 2009) 
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Pattern recognition receptors (PPRs) 
PPRs consist of several different families such as Toll-like receptors (TLRs), 
NOD-like receptors (NLRs), C-type lectin receptors (CLRs), RIG-I-like receptors 
(RLRs) and DNA-sensing molecules (Figure 1). However only the TLRs and NLRs play 
important roles in the recognition of bacterial infections (Kumar et al, 2013; Mogensen, 
2009).  
Compared to other PPR families, TLR family has been characterized in more 
detail. TLRs are expressed in different immune cells, as well as non-immune cells. Each 
member contains an extracellular domain containing leucine-rich repeats (LRRs) and a 
cytosolic Toll/interleukin-1 receptor homology (TIR) domain (Akira & Takeda, 2004). 
The binding of the ligand to LRR domains induces the dimerization of TLRs in the form 
of either homodimers or heterodimers, which triggers intracellular signal cascades. So 
far, 13 different mammalian TLRs with corresponding ligands have been identified 
(Mogensen, 2009). For instance, multiple ligands of TLR2, such as bacterial 
peptidoglycans or triacyl lipopeptides, bind the TLR2/TLR1 heterodimer (Liang et al, 
2009), while lipoteichoic acid binds the TLR2/TLR6 heterodimer (Irvine et al, 2013). 
TLR4, the first TLR identified in human, senses LPS from Gram-negative bacteria 
(Poltorak et al, 1998). TLR 5 and TLR9 recognize Flagellin and CpG DNA, respectively 
(Bauer et al, 2001; Hayashi et al, 2001; Wolf et al, 2011). Overall, TLR signaling is 
pivotal in the defense against microbial infections, as TLR knockout mice are 
significantly more susceptible to microbial challenges, compared to wild type mice 
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Figure 2  Domain structures of human NLRs(Zhong et 
al, 2013) 
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(Koedel et al, 2003; Lammers et al, 2012; Seibert et al, 2010; Shen et al, 2010; Sing et 
al, 2003; Takeuchi et al, 2000; Wieland et al, 2011; Wiersinga et al, 2007).  
            NLRs are cytosolic sensors, which can recognize intracellular bacteria (Kumar et 
al, 2013; Mogensen, 2009). Most members contain an N-terminal CARD domain which 
initiates immune signal cascades, a central nucleotide binding domain (NOD) and a C-
terminal leucine-rich region (LRR) which mediates ligand binding (Figure 2). Among 
this family, NOD1 and NOD2 play a role in bacterial infections (Carneiro et al, 2004). 
NOD1 can be activated by the cell wall component - diaminopimelic acid (DAP) from 
bacteria (Cardenas et al, 2011; Girardin et al, 2003a). Furthermore, NOD1 deficient mice 
are more susceptible to bacterial infections (Clarke et al, 2010; Viala et al, 2004). NOD2 
senses muramyl dipeptide (Girardin et al, 2003b) and NOD2 deficiency was reported to 
increase the susceptibility to bacterial infections (Kim et al, 2008; Kobayashi et al, 2005) 
  
Antimicrobial peptides  
Antimicrobial peptides (AMPs), also called host defense peptides (HDPs), 
generally contain 12 to 50 amino acids with a large proportion of positive charges and 
hydrophobic residues (Hancock & Sahl, 2006). These molecules have different 
secondary structures (Fjell et al, 2012) and can be abundantly secreted from barrier 
epithelia, phagocytic cells, fat body and some organs such as liver during infections 
(Ganz, 2003; Hancock & Sahl, 2006).  
The mechanisms of anti-bacterial activity by AMPs vary by bacterial species and 
AMP. In most cases, the molecular killing mechanism is not well characterized (Nizet, 
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2006), but it is believed that the major target is the bacterial cytoplasmic membrane. 
Most of bacterial surface membranes are hydrophobic and carry net negative charges, 
which might interact with positively charged AMPs. Consequently, bacteria might be 
killed via three major possible mechanisms: 1. High concentration of AMPs on the 
bacterial surface may interrupt the equilibrium of ion concentration via a disrupted 
membrane; 2. AMPs bind to  bacterial surfaces and form pores in the membrane, leading 
to the lysis of the cell; 3. AMPs enter bacterial cell through a disrupted membrane and 
interact with unknown ligands that are associated with DNA, RNA and protein synthesis 
or other critical metabolism pathways within the cell (Hancock & Sahl, 2006).   
Besides direct bacterial killing, most of AMPs have immunomodulatory 
properties (Hilchie et al, 2013). It is reported that some AMPs, which lack antibacterial 
activities in vitro, protect against Gram-positive bacteria or Gram-negative bacteria 
infection in vivo (Hancock & Sahl, 2006). For example, innate defense–regulator 
peptide (IDR-1), a well-studied peptide, is known to regulate immune system during 
bacterial infections (Hilchie et al, 2013; Nijnik & Hancock, 2009). It doesn’t have direct 
antimicrobial activity, but through increasing expression of chemokines (Hilchie et al, 
2013), it prevents infections from a variety of bacteria including methicillin-resistant 
Staphylococcus aureus (MRSA) (Hou et al, 2013), vancomycin-resistant Enterococcus 
(Scott et al, 2007)  and Salmonella enterica serovar Typhimurium (Scott et al, 2007).   
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Figure 3     Complement pathway activations and their basic functions 
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Complement system  
The complement system consists of over thirty different types of heat-sensitive 
glycoproteins and proteins, most of which are synthesized by the liver and circulating in 
the blood as protein precursors (Gasque, 2004). When a host is infected by microbes, 
complement pathways are activated, resulting in opsonization of bacteria by C3b, which 
can be recognized by C3b receptors presented on macrophages and neutrophils, 
recruitment of phagocytes by anaphylatoxins C3a and C5a, as well as the lysis of the 
bacteria mediated by  membrane attack complex (MAC) formation. 
The complement system was discovered earlier than PPRs and AMPs. In 1896, 
Jules Bordet found some heat-sensitive components in the serum that had non-specific 
antimicrobial activity (Laurell, 1990). These components were likely to be a part of the 
complement system, a term introduced by Paul Ehrlich in the late 1890s. Nowadays, the 
complement system is known to act through three distinct pathways: the classical 
pathway (CP), the lectin pathway (LP) and the alternative pathway (AP), which have 
different activation mechanisms but will converge to a C3 convertase, followed by the 
cleavage of the central complement component C3 (Figure 3). 
 
Complement activations  
The CP is initiated by the C1 complex, which consists of C1q, C1r and C1s, 
binding to immobilized antibodies on the surface of bacteria. These bindings will 
activate the protease C1r, and subsequently cleaves the C1s precursors into active C1s 
that cleaves C4 and C2 into C4b/C4a and C2b/C2a, respectively. C4b attaches to the cell 
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Figure 4 The classical complement pathway(Ricklin et al, 
2010) 
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surface via a covalent thioester bond and binds to C2a to form C3 convertase, which 
cleaves C3 into C3a and C3b. Some of the C3b molecules attach to bacterial surfaces, 
which can be recognized by C3b receptors on macrophages or neutrophils to enhance 
phagocytosis (Figure 3). Other C3b molecules interact with C3 convertase to form the 
C5 convertase that binds C5 and cleaves it into C5b and C5a. C5a and C3a are 
anaphylatoxins that act as chemokines to attract immune cells such as macrophages and 
neutrophils to the infection sites. On the other hand, C5b attaches to the cell surface and 
interacts with C6, C7, C8 and C9 to form the membrane attack complex (MAC), leading 
to the lysis of the cells (Figure 4).  
The activation of LP is similar to CP activation (Figure 5), both of which utilize 
C4b and C2a to form a C3 convertase. However, instead of activation through the 
binding of C1 complex to an immune complex, LP is activated using mannose-binding 
lectin (MBL) or ficolin associated with proteases MASP-1 and-2, (MBL-associated 
serine protease-1 and 2) respectively to form a complex, which interacts with 
carbohydrates, such as S. aureus wall teichoic acid, on the bacterial surface (Kurokawa 
et al, 2013).  This binding will activate MASP-1 and MASP-2, which cleave C4 and C2 
to form C3 convertase.  Compared to the other two complement pathways, LP is not well 
characterized and more complicated, based on the controversial structures or functions 
of MASP and MBL-associated proteins. Previously, scientists demonstrated that MASP-
1 or MASP-2 only form a homodimer (Chen & Wallis, 2001). However, Péter G et al 
found evidence that the MASP-1 and MASP-2 form a heterodimer, which is similar to a 
C1r and C1s heterodimer in the CP (Parej et al, 2014). Another controversial issue is the 
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Figure 5     Complement 
activations(Foster, 2005) 
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function of MASP-3. Some reports demonstrated that active recombinant MASP-3 
cleaved and activated C3 convertase (C3H2O-factor B) and factor D, in order to initiate 
alternative pathway activation (Iwaki et al, 2011). Meanwhile, functional studies using 
patient samples with nonsense mutations in MASP or deficiency in both MASP-1 and 
MASP-3 showed that neither MASP-1 nor MASP-3 affects the alternative pathway 
(Degn et al, 2012). More interestingly, some reports indicated that MBL-associated 
proteins act as complement regulators, but the biological significance of this effect 
hasn’t been well determinated (Degn et al, 2013).    
AP is distinct from CP and LP (Figure 5).  Activation can occur spontaneously 
through the binding of hydrolyzed C3 (C3H2O) to factor B, which is then cleaved by 
factor D to form an active C3 convertase (C3bBb). This new complex cleaves C3 into 
C3a and C3b, which binds to the microbial surface. Opsonized C3b can bind to factor B, 
followed by cleavage by factor D to form C3bBb.  Another C3b fragment binding to the 
C3 convertase forms C5 convertase (C3bBbC3b), resulting in the cleavage of C5 and the 
initiation of MAC formation.  
 
Complement regulation 
The complement system is a very powerful component of the innate immune 
defense. Overactivation of the complex system leads to excessive inflammation and 
damages host tissues and may play a role in many diseases such as Alzheimer's 
syndrome, schizophrenia, atypical hemolytic-uremic syndrome, angioedema, macular 
degeneration, and Crohn's disease (Tichaczek-Goska, 2012), Thus proper control of this 
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system is critical for human health. In order to prevent over-activation of the 
complement system, human blood contains a high level of complement regulatory 
proteins such as C1 inhibitor (C1INH), C4-binding protein (C4BP), factor H (fH) and 
factor I (fI). Some regulatory proteins are present on the membranes of host cells, such 
as complement receptor 1 (CR1), decay-accelerating factor (DAF) and CD59, to 
suppress complement activation on host cells. These molecules control and regulate 
different stages of complement activation using distinct inhibition mechanisms. A 
general description of the roles of these molecules in the regulation of the complement 
activation is presented in Table. 1. 
 
C1q and the C1 complex 
C1q has a molecular weight of around 460,000 Da (Hu et al, 2010). Unlike most 
complement proteins, C1q is synthesized by macrophages and dendritic cells, but not 
hepatocytes (Lu et al, 2008). C1q has six “arms”, each of which is assembled from three 
different poly-peptide chains: A chain (26,000 Da), B chain (25,000 Da) and C chain 
(24,000 Da).  Each arm has a C- terminal globular “head” domain, which interacts with 
the Fc domain of antibodies to initiate CP activation, followed by a collagen-like triple 
helix domain, which contains a repeating Gly-Xaa-Yaa sequence (Gaboriaud et al, 
2004). These six “arm” collagen-like triple helixes are held together to form an N-
terminal “stalk” (Figure 6). Under the electron microscope, C1q exhibits a “bouquet” 
like structure with an average angle of each arm at about 41º±19º, which indicates that 
C1q is a flexible molecule (Knobel et al, 1975). 
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Table 1    Complment regulators and their functions 
Table 1.  Complement regulators and their functions 
 
Regulators Alternative 
name 
Pathways Ligands Functions Refs 
C1INH N/A CP, LP C1r,C1s  
MASP-1,  
MASP-2 
Binds to C1r/C1s and 
MASP-1/-2; 
Prevents activation of 
C1 complex  
(Davis et al, 2008) 
C4BP N/A CP, LP C4 Binds to C4b and 
displace C2a; 
Co-factor for C4b 
cleavage by fI 
(Blom et al, 2004) 
FactorH N/A AP C3b and 
C3d 
Binds C3b and 
displaces Bb; 
Co-factor for C3b 
cleavage by fI 
(Rodriguez de 
Cordoba et al, 2004) 
Factor I N/A CP, LP, AP C3b and 
C4b 
Cleaves C3b and C4b; 
Aided by 
fH,MCP,C4BP or CR1 
(Nilsson et al, 2011) 
FHL1 N/A AP C3b Co-factor for C3 
cleavage by fI 
(Zipfel & Skerka, 
1999) 
Properdin Factor P AP C3 Stabilizes AP 
convertase 
(Hourcade, 2006) 
S-protein  Vitronecti
n 
CP, LP, AP MAC Prevents MAC insert 
into cell membrane  
(Milis et al, 1993) 
Clusterin SP-40 CP, LP, AP MAC Prevents MAC insert 
into cell membrane 
(Tschopp et al, 
1993) 
CR1 CD35 CP, LP, AP C3 Binds C4b and C3b; 
Displace C2a and Bb; 
Co-factor for C3b and 
C4b cleavage by fI 
(Fearon, 1985) 
MCP CD46 CP, LP, AP C3 Promotes C3b and 
C4b inactivation by fI 
(Hakulinen et al, 
2004) 
DAF CD55 CP, LP, AP C3 Binds and dissociates 
C3 convertase 
(C4bC2a and C3bBb)  
(Harris et al, 2007) 
CD59 Protectin  CP, LP, AP MAC Inhibits MAC 
formation  
(Kimberley et al, 
2007) 
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Figure 6  Structure models of C1q(Gaboriaud et 
al, 2004) 
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Besides binding to the immune complex, C1q can interact with many additional 
molecules and these interactions have different biological consequences (Table 2). The 
C1r2/C1s2 tetramer interacts with the collagen-like domain of C1q to form the C1 
complex (Wallis et al, 2010). This binding will pull “arms” of C1q closer together. After 
the C1 complex binds to antibodies, the “arms” of C1q will move apart again, which 
induces the autoactivation of C1r. Active C1r cleaves C1s into the active form, leading 
to the activation of the downstream C4 and C2 to form C3 convertase (Figure 7). 
Another well-studied C1q ligand is calreticulin (CRT), which interacts with C1q and the 
surface receptor CD91 to assemble into a C1q-CRT-CD91 complex that enhances 
apoptotic cell phagocytosis (Figure 8). C1q also interacts with 21 integrin, which will 
mediate the interaction of C1q with some immune cells and epithelial cells. This system 
could be hijacked by Bacillus anthracis spore surface protein BclA, which mediates 
spores invasion of epithelial cells (Xue et al, 2011).  
In addition to the role in CP and the clearance of apoptotic cell (Figure 8 and 
Figure 9), C1q is also involved in different immune cell activities including 
differentiation, cytokines expression, blood coagulations etc (Nayak et al, 2010). 
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Figure 7     The strained- to- releaxed model of C1 activation 
 18 
 
 
 
Table 2    C1q ligands and receptors 
Table 2.  C1q ligands and receptors  
C1q ligands  
or receptors  
Binding site(s) 
on C1q 
Effects/ functions Refs 
C1r2/C1s2  CLR Form C1 complex (Wallis et al, 2010) 
Antibodies  gC1q Initiate CP (Gadjeva et al, 2008) 
CRT Stalk Enhance AC phagocytosis (Paidassi et al, 2011) 
21 
integrin 
CLR Cells adhesion to C1q (Zutter & Edelson, 
2007) 
CRP gC1q Clearance of apoptotic/necrotic 
cells 
(McGrath et al, 2006) 
gC1qR gC1q Production of proinflammatory factors 
and regulation of cell functions 
(Peerschke et al, 1994) 
CD 91  N/A Enhance AC phagocytosis (Duus et al, 2010) 
PTX3 gC1q Inhibition of C1q-mediated 
complement activation and 
phagocytosis of apoptotic cells 
(Baruah et al, 2006) 
Decorin CLR Inhibition of C1q-mdicated 
complement activation  
(Krumdieck et al, 1992) 
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Complement component 3 (C3) 
C3 is a central molecule in the complement system. The three pathways converge 
at C3, which is cleaved into C3a and C3b by C3 convertase (C4bC2a or C3bBb). C3 
consists of  (110 kDa) and  (75kDa) chains, which are linked by a single disulfide 
bond (Figure 10). 
C3 is reported to be the most multifunctional molecule in the complement system 
(Lambris, 1988) and its functions are regulated through a series of cleavages mediated 
by specific proteases (Figure 10).  The cleavage of C3 mediated by C3 convertase will 
release C3a (9 kDa) from the N-terminus of  chain (figure 10). This subsequently 
induces a large conformational change in the remaining protein to form C3b, in which 
the thioester bond is exposed to covalently attach to cells or bacterial surfaces (Gros et 
al, 2008). C3b can be further cleaved in the  chain into inactive smaller fragments such 
as iC3b, C3c and C3d, mediated by factor I in complex with co-factors such as factor H, 
or MCP (Figure 10).   
C3a, a small complement peptide that triggers the degranulation of the immune 
cells, plays an important role in regulating the innate and the adaptive immune responses 
(Peng et al, 2009). C3a executes their functions by binding to a specific receptor, C3aR, 
which is a G Protein Coupled Receptor. C3b, another fragment of C3, opsonizes bacteria 
or apoptotic cells, which can be recognized by many immune cells expressing C3b 
binding receptors, leading to the enhancement of the phagocytosis (Law, 1988). 
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Figure 8Clearance of apoptotic cells by C1q indirect binding 
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Figure 9 Clearance of apoptotic cells by C1q- mediated CP 
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Staphylococcus aureus and diseases 
Staphylococcus aureus was first isolated and identified in 1880 by Sir Alexander 
Ogston (Cheng et al, 2011). It is a Gram-positive commensal bacterium and 80% of the 
population intermittently or persistently carry it in the nasal cavity (Nouwen et al, 2006). 
Once the host immune system and/or the physical barrier of external epithelium are 
compromised, S.aureus can enter the body and cause life-threatening diseases. It is 
reported that S.aureus is the most common cause of hospital- acquired infection, ranging 
from minimal skin infection to serious diseases including  bacteremia, endocarditis, 
arthritis and osteomyelitis (Melzer et al, 2003). In 2005, according to CDC, S.aureus 
killed more people than HIV in the United States (Centers for Disease & Prevention, 
2007) and importantly, currently there is no effective vaccine against S.aureus.  
Bacterial bloodstream infection is also named bacteremia, which will induce 
cellular and the humoral immune responses, causing increased population of both anti- 
and pro-inflammatory molecules (Nystrom, 1998). S.aureus is one of the major causes of 
bacteremia with high morbidity and mortality in the United States (Styers et al, 2006). 
The clfB and fnbA are two most frequently detected virulence genes in isolates of 
S.aureus obtained from patients with bacteremia. Interestingly, cna was also detected in 
some of these S.aureus isolates (Chi et al, 2010).  
Infective endocarditis is associated with cardiac endothelium damage caused by 
several different reasons such as valve implants (Hienz et al, 1996; Patti et al, 1992).  
These injuries expose the extracellular matrix, which will provide colonization sites for 
S.aureus. At the same time, platelets and fibrin will deposit over the damage sites, in 
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Figure 10 Domain organization of C3 and other C3 small fragments(Janssen et 
al, 2005) 
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order to heal them. These healing systems also provide a “shield” for S.aureus to prevent 
recognition by phagocytes such as macrophage and neutrophil. Previous studies 
demonstrated that in rat model, Cna, collagen adesin from S.aureus, facilitates the 
adherence of bacteria to endothelia cells in vitro and is a critical virulence factor in 
infective endocarditis (Hienz et al, 1996). 
Even though arthritis and osteomyelitis are two distinct diseases, they might 
share similar pathogenesis caused by S.aureus induced inflammation. Several reports 
demonstrated that Cna-expressing S.aureus specifically attaches to cartilages in vitro and 
animal studies indicated that Cna plays an important role in experimental arthritis and 
osteomyelitis by inducing cytokine expression (Elasri et al, 2002; Patti et al, 1994; Xu et 
al, 2004b). Nevertheless the exact molecular pathogenesis of arthritis and osteomyelitis 
elicited by S.aureus remains unclear. It is believed that once S.aureus enters the blood, it 
can eventually attach to cartilages within the joints. After colonization, S.aurues can 
release many molecules to evade the immune system. In turn, the innate immunity such 
as the complement system and immune cells will also recognize S.aurues and release 
cytokines and chemokines that attract more immune cells to the infection site, resulting 
in inflammation. In the end, over-active inflammations will damage cartilages and 
bones, leading to the erosion of these tissues.   
 
General mechanisms of S.aureus infection 
S.aureus also employs basic four-step approach to infect human: attachment, 
colonization, evasion and invasion. Attachment is critical for infection. S.aureus 
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expresses a group of surface protein named MSCRAMMs, which stands for microbial 
surface components recognizing adhesive matrix molecules (Rivera et al, 2007). This 
family of surface proteins helps S.aureus attach to extracellular matrix such as collagen, 
fibrinogen and fibronectin. After attachment, S.aureus will increase bacterial colony and 
grow into large clusters. In some circumstance, S.aureus will form biofilm, which is a 
highly organized bacterial community composed of extracellular DNA, proteins, 
polysaccharides and bacterial cells (Scherr et al, 2013). At the same time, S.aureus 
employs strategies to evade the host immune systems. In turn, immune systems use 
immune cells, complement system and other components of the host defense to monitor 
and eliminate S.aureus. The reciprocal interaction establishes a balance between 
S.aureus and the host immune system. Once the immune system is compromised, the 
S.aureus virulence factors will cause clinically manifested diseases. 
 
MSCRAMMs 
MSCRAMMs play a critical role in the bacterial attachment. So far, various 
MACRAMMs have been identified in different bacterial species. S.aureus has eight 
different MSCRAMMs, such as collagen- binding MSCRAMMs Cna, fibronectin-
binding MSCRAMMs FnBPA and FnBPB, fibrinogen-binding MSCRAMMs ClfA and 
SdrE (Bbp). Recent studies suggest that MSCRAMMs may also participate in 
complement evasion.  
 
 
 26 
 
 
 
Table 3  S.aureus MACRAMMs and their known ligands 
 Table 3. S.aureus MACRAMMs and their known ligands  
MSCRAMMs  Known ligands  
FnBPA Fibrinogen, Fibronectin, Elastin 
FnBPB  Fibrinogen, Fibronectin 
Cna Collagen, C1q, MBL 
ClfA  Fibrinogen, Complement factor I 
ClfB  Fibrinogen, Keratin  
SdrC Beta-Neurexin 
SdrD Unknown  epithelial  cell surface  component 
SdrE(BBp)   Fibrinogen, Bone Sialoprotein, FH, C4BP 
 
 
 
 
Collagen-binding MSCARMMs from Gram-positive bacteria  
Collagen, the most abundant ECM molecules in the human body, makes up over 
25% of the whole-body protein. To date, over 20 genetically distinct collagen types have 
been identified and the majority of the collagens are present in different multimeric 
structures (Lozano et al, 1985). The collagen monomer forms a characteristic triple 
helix, which consists of three polypeptide chains with repeated “Gly-Xaa-Yaa” motifs in 
the amino acid sequence (Zong et al, 2005). Bacteria have evolved to express structural 
related collagen-binding MSCRAMMs, which interact with the triple helix.  
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Figure 11Schematic of collagen-binding MSCRAMM domain organization 
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S.aureus Collagen-Binding MSCRAMMs-Cna 
Cna, Collagen-binding MSCRAMMs from Staphylococcus aureus, was 
identified in 1994 by our lab (Patti et al, 1994) and has been well characterized for 20 
years. Cna contains an N-terminal signal peptide, an A domain which is responsible for 
collagen binding followed by B-repeats, which are suggested to help A domain display 
on the surface of bacteria, and the C-terminal cell wall attachment elements, including a 
cell wall anchoring region, a transmembrane segment and a positively charged 
cytoplasmic tail (Figure 11). Actually, the collagen binding domain of Cna only contains 
N1 and N2 subdomains. Previously, our lab crystalized CnaN1N2 domains (Figure 12A) 
and Cna N1N2 in complex with collagen triple helixes peptide (Figure 12B).  These 
crystal structural data indicate that Cna-collagen interaction follows a multi-step ligand 
binding mechanism named “collagen hug model” (Figure 13).  In this model, the 
collagen triple helix peptide interacts with Cna N2 subdomain and this binding will 
redirect N1-N2 linker with N2 subdomain to “hug” the collagen triple helix peptide.  In 
the end, C terminal “latch” domain of N2 subdomain interacts with N1 subdomain, 
resulting in the stabilization of this complex (Zong et al, 2005). This model also 
indicates that the interaction is dominated by the rope-like structure of the collagen 
(Zong et al, 2005). 
Previous studies have proved that Cna is a virulence factor in several animal 
models of infectious diseases such as endocarditis, arthritis, keratitis and osteomyelitis 
(Hienz et al, 1996; Johansson et al, 2001; Rhem et al, 2000; Xu et al, 2004b) and that the 
virulence potential is associated with its affinity to collagen (Xu et al, 2004b). In the 
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septic arthritis mouse model, the role of Cna was examined by comparing the virulence 
among S.aureus expressing wild type CnaN1N2, and Cna mutant with a single point 
mutation resulting in the loss of collagen binding. These results demonstrated that the 
virulence of S.aureus depends on Cna’s collagen-binding ability (Xu et al, 2004b).  
However, interestingly, the data also showed that Cna doesn’t contribute to the early 
colonization of S.aureus (Xu et al, 2004b).  
 
Cna-like Collagen-Binding MSCRAMMs from different species 
Collagen-binding MCRAMMs are also found in several different species, such as 
Ace from Enterococcus faecalis (Nallapareddy et al, 2003), Acm from Enterococcus 
faecium (Hubble et al, 2003), Cne from Streptococcus equi (Lannergard et al, 2003) and 
Cnm from Streptococcus mutan (Nakano et al, 2010). They all share similar structural 
domain organizations (Figure 11). The collagen binding mechanism of all these 
structurally related collagen-binding MCRAMMs seems to be similar and all of them 
facilitate the adherence of bacteria to the collagen, leading to infections. 
Sequence alignment analysis reveals that the amino acid sequences of Cna, Ace, 
Acm, Cne and Cnm have some similarities, especially on the N2 subdomain containing 
collagen binding sites. The N2 subdomain of Cna shares 55%, 49% and 48% amino acid 
sequence identity with those of Cnm, Acm and Cne respectively.  
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Figure 12Crystal structures of Cna and Cna-collagen-like peptide complex 
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Figure 13 A hypothetical 
‘Collagen Hug' model 
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             S.aureus fibrinogen-binding MSCRMMs 
S.aureus expresses several fibrinogen (fg) -binding MSCRAMMs, most of which 
belong to Sdr family of surface proteins, such as ClfA, ClfB, SdrE/Bbp. Although they 
bind to different sites of fibrinogen (Figure 14), these proteins share similarities in both 
the domain organizations and the structure of ligand binding domain (Figure 15). Most 
of them comprise an A region at N-terminus which is responsible for fibrinogen binding, 
followed by B-repeat region and R domain containing the Ser-Asp (SD) dipeptide 
repeats. The C terminus contains cell wall attachment elements. Specifically, the A 
region contains three subdomains: N1, N2 and N3, whereas the fibrinogen binding 
domain only contains N2N3 subdomain. Crystal structural analysis of N2N3 of ClfA and 
ClfB showed that the fg-binding domain consists of two Ig-like folds, which are 
connected by a polypeptide “linker” (Ganesh et al, 2008; Ponnuraj et al, 2003; Xiang et 
al, 2012).  
Like the collagen-binding mechanism, Fg-binding also employs multi-step 
binding mechanism named “Dock, Lock and Latch” model. Take SdrG from S. 
epidermidis for example: the open form of SdrG allows Fg peptide to “dock” its N2 
subdomain binding trench. This binding induces a conformational change at the C-
terminal strand, which then interacts with Fg peptide and “locks” it. Further redirection 
of the C-terminal strand results in a -sheet of C-terminal complement with the N2 
domain (Latch) (Ponnuraj et al, 2003).  
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Complement evasion by S.aureus 
The complement system helps the immune system to recognize and kill 
pathogens. In return, numerous successful pathogenic bacteria, especially S.aureus, have 
evolved many well-defined strategies to evade it. Most bacteria evasion strategies can be 
categorized into three major mechanisms: direct inhibition, recruitment of complement 
regulators and the degradation of complement components (Lambris et al, 2008 and 
Table 4). S.aureus expresses several molecules to inhibit complement activation directly. 
Protein A (SpA), expressed by most of the clinical S.aureus strains (Votintseva et al, 
2014), is a very critical virulence factor, which has multiple strategies to evade immune 
system, including complement activation. It binds to the Fc of the antibody, which 
interrupts the opsonization of antibodies and the formation of immune complexes 
(Kronvall & Gewurz, 1970). S. aureus extracellular fibrinogen-binding protein (Efb), 
Extracellular complement-binding protein (Ecb) and staphylococcal complement 
inhibitor (SCIN) directly bind and inhibit C3 convertase activity (Jongerius et al, 2010a; 
Jongerius et al, 2010b; Lee et al, 2004; Rooijakkers et al, 2005). Chemotaxis inhibitory 
protein of S. aureus (CHIPS) binds C5a receptor and blocks phagocyte recruitment 
(Postma et al, 2005; Rooijakkers et al, 2006). For the regulator recruitment, S.aureus 
Bbp or SdrE binds to the complement regulators C4b-binding proteins and factor H, 
which block bacteria phagocytosis by facilitating the decay of C3 convertase (Hair et al, 
2013; Sharp et al, 2012); Clumping factor A (ClfA) of S.aureus was shown to recruit 
factor I and enhances the cleavage of C3b to iC3b (Hair et al, 2010). In addition, the 
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Figure 14Fg-binding 
MSCRAMMs bind to different 
sites of fibrinoge(Yee et al, 1997) 
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Figure 15 Domain orgnazation of 
Sdr protein family(Foster & 
Hook, 1998) 
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metalloprotease aureolysin of S.aureus degrades C3 (Laarman et al, 2011; Lambris et al, 
2008). 
 
 
 
 
Table 4   Complement evasion by S.aureus 
 Table 4. Complement evasion by S.aureus 
Complement evasion poteins Target  
Direct inhibition    
Protein A( SpA) Antibodies   
Efb/Ecb C3 and C3b  
SCIN C3 convertase  
CHIPS C5aR  
SSL-7 C5  
   
Recruitment of complement regulators   
ClfA Factor I  
Bbp or SdrE Factor H and C4BP  
   
Degradation of complement components   
Staphylokinase C3b and antibodies  
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CHAPTER II  
MATERIALS AND METHODS

 
 
Antibodies  
Polyclonal goat anti-human C1q, goat anti-human C4 antibodies and goat anti-
human C3 antibodies were purchased from Complement Technology (Tyler, Texas). 
Monoclonal anti-C1q antibody was purchased from Quidel (San Diego, CA). Goat anti–
human C1r and sheep anti-human C1s polyclonal antibodies were from R&D systems 
(Minneapolis, MN). Rabbit anti-goat and rabbit anti-sheep polyclonal antibodies 
conjugated with HRP were from Invitrogen (Carlsbad, CA). Monoclonal anti-poly His-
conjugated with HRP-antibody was supplied by Alpha Diagnostic (San Antonio, Texas) 
and human IgM was ordered from EMD Chemical (Philadelphia, PA). 
 
Reagents  
Purified human C1q, C1r, C1s, factor B, factor D, C3, C3b, C3c, C3d, C4b, C5  
normal human serum (NHS), C1q-Depleted serum (C1q-dpl), factor B depleted serum 
(fB-dpl), factor H depleted serum(fH-dpl), rabbit erythrocytes (ER) and antibody- 
sensitized sheep erythrocytes (EAs) were obtained from Complement Technology  
____________ 
* Part of this chapter is reprinted with permission from “Collagen-binding microbial 
surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-
positive bacteria inhibit complement activation via the classical pathway” by Kang M, 
Ko YP, Liang X, Ross CL, Liu Q, Murray BE, Höök M., 2013. The Journal of 
Biological Chemistry, 288, 20520-20531, Copyright [2013] by American Society for 
Biochemistry and Molecular Biology. 
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(Tyler, Texas). Recombinant human type I collagen was from FibroGen (San 
Francisco,CA). Human fibrinogen was from Enzyme Research and o-phenylenediamine 
dihydrochloride (SigmaFast) was purchased from Sigma. 
 
Expression and purification of recombinant proteins  
Expression plasmids were generated as described in the previous studies (Rich et 
al, 1999b; Symersky et al, 1997). Briefly, the DNA encoding the N1N2 domains of 
collagen-binding MSCRAMMs or fibrinogen-binding MSCRAMMs Bbp and SdrE were 
subject to PCR and ligated into pQE30. The primers for cloning PCR-generated N1N2 
regions and mutants integrated into expression vector pQE-30 (Qiagen Inc., Chatsworth, 
CA) are listed in Table 5. The Cna mutants harboring the mutations in N1N2 domains 
were generated by using QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) 
according to the manufacturer’s instructions. E. coli Topp3 (Stratagene) containing the 
pQE30-derived plasmids were grown overnight at 37°C in LB containing 100 µg/ml 
ampicillin. The overnight cultures were diluted 1:50 into fresh LB medium, and the 
expression of the recombinant proteins was induced with 0.2 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 5 hours at 37°C. Bacteria were harvested by 
centrifugation and lysed using a French press (SLM Aminco). Soluble His6-tagged 
recombinant proteins were purified through a HisTrap HP Column and a HiTrap Q HP 
column (GE Healthcare) according to the manufacturer’s manual. The Purified proteins 
were analyzed by SDS-PAGE and appropriate fractions were dialyzed into TBS or PBS 
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and stored at -20°C. Protein concentrations were determined by absorption spectroscopy 
at 280 nm using calculated molar absorption coefficient values. 
 
 
 
 Table 5Oligonucleotides for Cna mutants, Acm, Cne and Cnm constructs 
 Table 5. Oligonucleotides for Cna mutants, Acm, Cne and Cnm constructs  
Oligonucleotide
a
 Sequence (5’→3’) 
Flanking primers  
Acm 5’ GCGGGATCCGATGCAGGCAGAGATATCAGCAG 
Cne 5’ GCGGGATCCGCAACTAATCTTAGTGACAACATC 
Cnm 5’ GCGGGATCCAGTGATGTCAGCAGTAACATTTC 
Acm 3’ GCGGTCGACTTAAATCTCTGTGTCATTGATATATTT 
Cne 3’ GCGGTCGACTTAAAAGCTGGTATAGCGACTGCC 
Cnm 3’ GCGGTCGACTTATGTAGTAGTGGTTGTTCTTCC 
Mutagenic primers  
QIE forward GAACGGGACAGATTGAAACAAGTAGTGTTTTCTATT
ATAAAACG 
QIE reverse GAAAACACTACTTGTTTCAATCTGTCCCGCTTCACT
TTTATG 
ΔEAG forward CGGTTCATAAAAGTACAAGTAGTGTTTTCTATTATA
AAACG 
ΔEAG reverse GAAAACACTACTTGTACTTTTATGAACCGTAACATT
CG 
Cna ∆EAGTSS 
forward 
CATAAAAGTGTTTTCTATTAT 
Cna ∆EAGTSS 
reverse 
ATAATAGAAAACACTTTTATG 
Cna ∆Latch forward 1 
Cna ∆Latch reverse 1 
Cna ∆Latch forward 2 
GGA TCC GCA CGA GAT ATT TCA TCA AC 
GTG CAC AAT ATT AAT GCT GTC GAC 
GTG CAC AAT ATT AAT GCT TAA GTC GAC CTG 
CAG CCA AGC 
Cna ∆Latch reverse 2 GCT TGG CTG CAG GTC GAC TTA AGC ATT AAT 
ATT GTG CAC 
a
Oligonucleotides were synthesized by the integrated DNA technologies, INC. 
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ELISA-type binding assays  
Wells on Immulon 4BHX plates (Thermo Scientific) were coated overnight at 
4°C with 1 μg of recombinant human collagen or purified human C1q. After blocking 
with 2% BSA in TBST (0.05% Tween 20, TBS) at RT for 2 hours, recombinant proteins 
were added to the wells and incubated for 1 hour at RT. Following incubation with HRP 
conjugated anti-His antibodies (10,000× dilution) at RT for 1 h, the substrate OPD was 
added. Bound proteins were quantified by measuring the absorbance at 450 nm in a 
microtiter plate reader (Thermomax) and data were analyzed by GraphPad Prism 
software. 
The competition assay used a protocol similar to that described above, with the 
following alterations. First, recombinant MSCRAMM was preincubated with C1 
complex or C1q (10 nM) in the HBS++ buffer (20 mM Hepes, 140 mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2 and 0.025% bovine serum albumin (BSA), pH 7.3) at RT for 1 h. 
The mixture was subsequently added to the microtiter plates previously coated overnight 
at 4°C with purified IgM (0.5 μg/well), C1r or C1s (0.5 μg/well). The following primary 
antibodies were used where applicable: goat anti-human C1q antibody (5000× dilution), 
goat anti-human C1r (2000× dilution) and sheep anti-human C1s (2000× dilution). 
Secondary antibodies rabbit anti-goat and rabbit anti-sheep and Sigma-fast OPD were 
used for the detection and visualization of the bound protein.  
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        Table 6 Proteins used in this study 
Table 6. Proteins used in this study (Kang et al, 2013) 
Name Description 
Cna31-344  Recombinant protein containing N1N2 domains of Cna of 
S. aureus with an N-terminal tail of 6 histidine residues  
Cna Y175K Cna31-344  with Y175K substitution  
Cna  ∆latch Cna31-344  without C-terminal ‘latch’ residual  
Cna QIE  Cna31-344  with insertion of 3 amino acids (QIE) from Ace 
linker to linker region (168^169)  
Cna ∆EAG Cna31-344  with deletion of 3 amino acids (EAG) from 
linker region (166-168) 
Cna 
∆EAGTSS 
Cna31-344  with deletion of 6 amino acids (EAGTSS) from 
linker region (168-171) 
Cne28-323  Recombinant protein containing N1N2 domains of Cne of 
S. equi with an N-terminal tail of 6 histidine residues 
Cnm32-323  Recombinant protein containing N1N2 domains of Cnm 
of S. mutans with an N-terminal tail of 6 histidine 
residues 
Acm29-320  Recombinant protein containing N1N2 domains of Acm 
of E. faecium with an N-terminal tail of 6 histidine 
residues 
Ace32-367  Recombinant protein containing N1N2 domains of Ace of 
E. faecalis with an N-terminal tail of 6 histidine residues 
Bbp 215-544 Recombinant protein containing N2N3 domains of Bbp of 
S. aureus with an N-terminal tail of 6 histidine residues 
SdrE 215-544 Recombinant protein containing N2N3 domains of SdrE 
of S. aureus with an N-terminal tail of 6 histidine 
residues 
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In the case of determining C1 complex binding to human IgM or Cna, microtiter 
wells were coated with 0.5 μg/well of human IgM or of rCna 31-344 and bound C1 
complex was detected using goat anti-human C1q (5000× dilution), goat anti-human C1r 
(2000× dilution) and sheep anti-human C1s (2000× dilution), followed by HRP 
conjugated rabbit anti-goat or rabbit anti-sheep antibodies (3000× dilution).  
To detect the binding of Bbp and SdrE to the immobilized human fibrinogen or 
purified human C3b, C5 and C3, Immulon 4BHX plates (Thermo Scientific) were coated 
with 1 μg/well human fibrinogen, C4b C3b, C3 or C5 at 4°C overnight. Coated wells 
were blocked for 2 hours at room temperature with 2% of BSA in TBST (0.05% Tween-
20). Increasing concentrations of Bbp or SdrE were added to the wells and incubated for 
1 hour at room temperature. Bound proteins were detected with anti-Bbp or SdrE 
specific antibodies (3,000 × dilution) followed by goat anti - rabbit antibodies-HRP 
(3,000 × dilution, Invitrogen).  
 
Bacterial attachment assay 
Adherence assay was performed as described previously (Xu et al, 2004b) with 
modification. S. aureus strain Phillips and correspondence Cna deletion mutant strain 
(PH100) (Patti et al, 1994) were grown in BHI media overnight and serial dilution of 
bacteria were made. Subsequently bacteria were incubated in the wells of microtiter 
plates coated with C1q (1 μg/well). Adhered bacteria were fixed with 4% formaldehyde 
and stained with 0.5% crystal violet. After washing, 50µL of 10% acetic acid was added 
and the absorbance at 590 nm was measured. 
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Surface plasmon resonance (SPR) analysis 
The interactions between C1q and Cna31-344 were characterized using a Biacore 
3000 (GE Healthcare/Biacore, Uppsala, Sweden) at 25°C. Sensor chip C1 and amine-
coupling kits were obtained from the same company and used to covalently attach 
ligands onto the sensor surface using amine coupling procedure as recommended by the 
manufacturer. During immobilization, HEPES-buffered saline (HBST: 10amM HEPES, 
pH 7.3, 150 mM NaCl and 0.005% Tween-20) was used as running buffer at a flow rate 
of 5 μl/min.  Following the activation of sensor surface, 5 μg/ml of ligand solution 
(collagen or Cna31-344 in 10 mM sodium acetate, pH5.5; C1q in 100 mM sodium 
phosphate buffer, pH7.0) was injected and coupled to the flow cell on a C1 chip.  A 
reference flow cell was prepared for each sensor chip with activation and deactivation 
steps where no protein was coupled. Binding was performed at a flow rate of 30μl/min 
with TBST (25 mM Tris, pH7.4, 3 mM KCl, 140 mM NaCl, and 0.01% Tween 20) as 
running buffer. To regenerate the sensor surface, bound Cna proteins were removed 
from the collagen surface by injecting 10 mM glycine (pH 1.5) for 30 second; bound 
C1q was removed with 0.5% SDS from the Cna31-344 surface. 
To analyze the binding of Bbp or SdrE to complement proteins C3, C3b, C3c, 
C3d or C5, complement proteins were immobilized onto a CM5 sensor chip, 
respectively. Various concentrations of Bbp or SdrE in the HBS buffer with 1 mM Mg
2+
 
were passed over the sensor chip at a flow rate of 50 µl/min. To regenerate the sensor 
surface, bound Bbp, SdrE or other complement proteins were removed from the surface 
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by injecting1M NaCl and 10 mM sodium tetraborae  (pH 8.5) for 60 seconds, 
respectively. 
In an on-chip convertase formation assay (Chen et al, 2010), a 1 to 1 ratio 
mixture of factor B and factor D (250 nM each) in the presence or absence of 50 µM 
Bbp as premixed solutions was injected onto the immobilized C3b chip for 2 min at 10 
µl/min to establish the C3 convertase formation. The association and disassociation rates 
of the C3 convertases were evaluated and compared. 
The analysis of factor B cleavage was detected and performed as described 
previously (Hourcade, 2006) on the Factor P immobilized sensor chip with C3b, mixture 
of C3b and factor B or plus factor D in the presence or absence of Bbp for 1 min. The 
binding of C3bBb was detected by analyzing the association and the disassociation rates.  
 The baseline corrected SPR response curves (with buffer blank run further 
subtracted) were used for affinity determination. For the steady-state analysis, the 
equilibrium response (Req) of each injection was collected and plotted against the 
concentration (A) of injected protein. A binding isotherm was fitted to the data 
(GraphPad Prism 4, GraphPad Software, Inc., La Jolla, CA, USA) to obtain the 
equilibrium dissociation constant (KD).   
     The non-equilibrium data were globally fit to a two-state model using 
BIAevaluation software (Version 4.1). Association and dissociation rate constants (ka1, 
kd1) for the binding state, and forward and backward rate constants (ka2, kd2) for the 
conformational change state were obtained from the fitting, and apparent dissociation 
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constant (KD
app
) was calculated from the rate constants: KD
app
 = 1 / ((ka1 / kd1) * (1+ka2 / 
kd2).   
 
Immunoprecipitation (IP) assay   
Monoclonal anti-human C1q antibodies were captured with protein G beads 
(Thermo Scientific) at RT for 2h. Subsequently, a mixture of the C1 complex (35 nM) 
and recombinant MSCRAMMs (80 μM) previously incubated at RT for 1-2 hours in 
HBS++ buffer were added to protein G beads bearing anti C1q antibodies and allowed to 
incubate for 2 h at 37°C. After washing the beads with HBS++ containing 0.1% Triton 
X-100 (Sigma), 50 μl of non-reducing buffer was added and proteins were denatured at 
95°C for 10 min. After centrifugation at 2500 × g for 5 min, 10 μl of supernatant was 
subjected to SDS-PAGE and transferred to nitrocellulose (Bio-rad). The component of 
the C1 complex was detected by polyclonal goat anti-human C1q (10,000× dilution), 
goat anti-human C1r (8000× dilution), or sheep anti-human C1s (8000× dilution) and 
followed by HRP-conjugated rabbit anti-goat (10,000× dilution) or rabbit-sheep 
secondary antibodies (10,000× dilution). Chemiluminescent substrate (SuperSignal West 
Pico from Thermo Scientific) was used to visualize the cross-reacting material. 
 
CP/LP C4b, C3b and C5b-9 complex deposition on ELISA  
C4b, C3b and C5b-9 complex deposition was performed as described ((Laarman 
et al, 2012; Rooijakkers et al, 2005) with slight modifications. 96-well Immulon 4BHX 
microtiter plates (Thermo Scientific) were coated with 0.1 μg of human IgM or 1 µg of 
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mannan (Sigma) overnight at 4°C. Diluted serum (in HBS++) was preincubated with 
various concentrations of recombinant proteins at RT or 37
o
C for 1 hour. After blocking 
the wells with 2% BSA in TBST (0.05% Tween 20, TBS) at RT for 2 hours, the serum-
protein mixtures were added and the plates were incubated for 1 hour at RT or 37
o
C. 
Bound-C4b, C3b and C5b-9 complex was detected by goat anti-human C4 antibody 
(10,000× dilution) goat anti-human C3 antibody (10,000× dilution) or mouse anti-human 
C5b-9 antibody (1,000× dilution), followed by horseradish peroxidase (HRP)-conjugated 
rabbit anti-goat antibody or goat anti-mouse antibody (10,000× dilution) for 1hour each 
and quantified as described above. 
 
AP C3b generation ELISA type assay  
Immulon 4BHX plates were coated with 1μg/well LPS at 4°C overnight. Coated 
wells were blocked with 2% of BSA in 0.5% Tween-PBS buffer for 2 hours at room 
temperature. Fixed concentrations of serum at 8% in HBS
o
 with 5 mM Mg
2+
 and EGTA 
plus 0.025% BSA, which were preincubated with various concentrations of recombinant 
proteins that we want to test, were added to wells and incubated for 1 hour at 37°C. The 
C3b generation was detected by goat anti human C3 antibody (10,000 × dilution) 
followed by rabbit anti-goat antibody (4000 × dilution). Color development was 
performed using SigmaFast OPD (Sigma) and the binding was measured using a 
microtiter plate reader (Thermomax, Molecular Devices) at 450 nm.  
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Hemolysis 
Complement-mediated hemolysis of EAs was performed as described previously 
(Itoh et al, 2010) with slight modifications. Briefly, NHS, C1q-dpl, or fB-dpl (final 
concentration 0.5%) was preincubated with the parent and the mutant collagen-binding 
MSCRAMMs in a final volume of 260 μl at room temperature (RT) for 1 hour. 
Subsequently, 40 μl of EAs (5 × 108 /ml) were added to the mixture, which was 
incubated at 37°C for 45 min. The clear supernatant was transferred to 96-well PVC flat-
bottom plate (Becton, Dickinson, BD) after centrifugation (2000 rpm, 10 min). The lysis 
of EAs was quantified by measuring the absorbance at 405 nm using microtiter plate 
reader (Thermomax, Molecular Devices). Data was present as the percentages of lysis by 
dividing with the absorbance value obtained from 100% EAs lysis. The data represent 
the mean ± SD of three independent experiments performed in triplicates (GraphPad 
Prism). All serums were diluted in BHepes buffer (20 mM Hepes, 140 mM NaCl, and 
0.025% bovine serum albumin (BSA), pH 7.3) containing 0.15 mM CaCl2, 0.5 mM 
MgCl2. 
 
S.aureus infection murine model 
All female mice (wild type and C1q knockout) between 8 and 12 weeks old were 
used in this infection murine model. The strains used were clinical S. aureus isolates 
Phillips strain and its cna knockout strain PH100. S.aureus were grown overnight in 
TBS, washed twice and suspended in PBS. Wild type mice and C1q knockout mice were 
infected with 3.5 × 10
7
 cfu Phillips or PH100 strain / mouse respectively and monitored 
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for body weight once a day. Mice that lost more than 30% weight were considered 
moribund and euthanized. 
 
Bacterial load in blood and organs 
Mice were killed at day 1 and day 6.5 after the infection. The blood was collected 
via cardiac puncture blood collection and immediately mixed with 50 µl of 1M sodium 
citrate. Organs were harvested and homogenized in PBS. Serial dilutions of the blood 
and the organ homogenates were cultured on TSA plates supplemented with/without 
proper antibiotic overnight at 37
o
C. CFUs were calculated as CFU/ml for blood and 
CFU per organ. 
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CHAPTER III 
THE COLLAGEN-BINDING MSCRAMM FROM S. AUREUS INHIBITS 
CLASSICAL PATHWAY ACTIVATION

 
 
Introduction 
Collagen, the most abundant protein in the human body, plays a critical role in 
human health and homeostasis. It has a unique triple helix structure which consists of 
three  chains with repeating Gly-X-Y sequences (Chung et al, 2004).  Through this 
highly regular arrangement of amino acids in each chain and the rope-like structure of 
collagen, it interacts with many proteins or proteinases. These interactions have essential 
biological significances, especially for adhesion molecules from pathogenic bacteria 
(Zong et al, 2005).  
Gram-positive bacteria express a group of structurally related collagen adhesins 
named collagen-binding MSCRAMMs (Figure 11), which are found in many bacterial 
species, such as Cna in Staphylococcus aureus (Patti et al, 1994) , Ace in Enterococcus 
faecalis (Liu et al, 2007), Acm in Enterococcus faecium (Nallapareddy et al, 2003), Cne 
in Streptococcus equi (Lannergard et al, 2003) and Cnm in Streptococcus mutans 
(Nakano et al, 2010). These molecules are well-characterized virulence factors in  
____________ 
 
* Part of this chapter is reprinted with permission from “Collagen-binding microbial 
surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-
positive bacteria inhibit complement activation via the classical pathway” by Kang M, 
Ko YP, Liang X, Ross CL, Liu Q, Murray BE, Höök M., 2013. The Journal of 
Biological Chemistry, 288, 20520-20531, Copyright [2013] by American Society for 
Biochemistry and Molecular Biology. 
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several experimental animal models of infectious diseases and mediate the adherence of 
bacteria to host tissues (Hienz et al, 1996; Johansson et al, 2001; Nakano et al, 2010; 
Nallapareddy et al, 2008; Rhem et al, 2000; Singh et al, 2010; Xu et al, 2004b).  
Cna from S.aureus is the prototype of collagen-binding MSCRAMMs. Structural 
analysis of Cna- triple helix peptide complex demonstrated that the rope-like structure of 
collagen is critical for this interaction (Zong et al, 2005). Besides collagen, a number of 
proteins contain collagen-like subdomains, some of which are involved immune system, 
such as C1q. C1q is an initiator of the CP, which is critical of the host’s defense against 
microbial infection. It is reported that several pathogenic bacterial proteins interact with 
C1q, leading to the aggravation of bacterial infections, such as BclA from Bacillus 
anthracis (Xue et al, 2011) and PepO from Streptococcus pneumoniae (Agarwal et al, 
2014).  I believe that the collagen-binding MASCRMMs also have similar functions.  
In this part of study, I report that the Cna-like family of collagen-binding 
MSCRAMMs also bind C1q and inhibit the complement classical pathway activation. 
The molecular bases for this inhibition are dissected and described. 
 
Results  
Cna binds to C1q  
A recombinant form of Cna, Cna31-344, bound to C1q or collagen type I coated in 
microtiter wells in processes that were dose dependent and exhibited saturation kinetics 
(Figure 16A). SPR analyses using C1q and collagen type I immobilized on BIA-
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Figure 16 . Cna binds to collagen 
and C1q 
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core chips corroborated our ELISA results and further indicated that the Cna31-344 
interaction with C1q involves a lower affinity compared to that with collagen type I 
(calculated KD of 12 μM and 91 nM, respectively) (Figure 16, C and B). However, when 
the system was reversed and Cna31-344 was immobilized, C1q bound to Cna31-344 with a 
much higher affinity (KD = 13 nM) (Figure. 16D). This phenomenon is consistent with 
what we observed for collagen binding to Cna coated chip, in which a significant higher 
affinity is also observed (calculated KD=0.4 pM) (Ross et al, 2012) compared to when 
Cna binds to collagen immobilized on the chip (calculated KD= 91 nM). The molecular 
explanation for this difference is presently unclear; however, the potential for a triple 
helix collagen monomer and a hexameric C1q to simultaneously bind multiple 
immobilized Cna31-344 molecules likely contribute to the observed differences.  
The ability of Cna to interact with C1q in the presence of serum was also 
evaluated in an ELISA-type assay in which Cna coated wells were incubated with NHS 
or C1q-dpl serum and bound C1q was detected by polyclonal anti-C1q antibody. The 
results showed that Cna indeed bound to C1q and/or C1 complex in NHS (Figure 16 E). 
This observation demonstrated that Cna is able to interact with C1q in its native 
condition. 
A clinical strain of S. aureus strain Phillip that expresses full length, native Cna 
on the bacterial surface and a correspondence Cna deletion mutant strain (PH100) were 
evaluated for their ability to bind to C1q coated surface. Only wild type Phillip strain 
that expresses full length Cna bound to C1q whereas the Cna deletion strain PH100 did 
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not (Figure. 16F). This result demonstrated that bacterial surface anchored native Cna 
protein interacts with C1q. 
 
Cna mutants with reduced affinity to collagen decrease affinity to C1q  
Our previous studies have demonstrated that the Y175 in N2 domain of Cna is 
important for collagen interaction (Symersky et al, 1997) and the linkers between N1 N2 
domain harboring insertions or deletions affect Cna binding to type 1 collagen (Ross et 
al, 2012). In addition, the latch segment found in the C-terminal extension of N2 is likely 
important for the interaction (Ponnuraj et al, 2003; Zong et al, 2005). Thus we have 
generated a panel of Cna mutants including a point mutation in the N2 domain resulting 
in loss of collagen binding (Y175K), extending or truncating the linker between the N1 
and N2 domains in Cna (QIE, ΔEAG and ΔEAGTSS) (Ross et al, 2012) and a deletion 
of the latch segment (Δlatch) (Figure 17A and Table 3). These mutants have altered 
collagen-binding activities compared to that of the wild-type Cna protein (Figure 17, B 
and D). The ability of these mutants to bind to C1q as compared to type 1 collagen was 
evaluated by ELISA-type binding assays and SPR analyses. Relative binding activities 
of these mutants to C1q closely tracked those to collagen (Figure 17, B and C), and the 
mutants that exhibited lower affinities for collagen also showed lower affinities for C1q 
in SPR experiments (Figure 17, D and E). In the ELISA binding assay, half-maximum 
binding for QIE, ∆latch, Y175K, ∆EAG, and ∆EAGTSS mutants to C1q was obtained at 
concentrations of 4.7, 15.3, 20.6, 32.9, and 39.1 μM, respectively, compared to wild-type 
Cna in which half-maximum binding was observed at a concentration of 1.4 
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Figure 17 Cna likely binds to the 
collagenous domain in C1q 
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μM (Figure 17 C). Taken together these results strongly suggest that Cna recognizes C1q 
and collagen type I in similar manners and indicate that Cna likely binds to the 
collagenous domains in C1q. 
 
Cna inhibits activation of the classical complement pathway  
The observed binding of Cna31-344 to C1q raised the possibility that the 
MSCRAMM could modulate complement activation. To explore this possibility, I used 
functional readouts for activation of the CP including a hemolytic assay and an ELISA-
type assay where I quantitated the deposition of C4b on antibody coated surfaces. 
Hemolysis of antibody-sensitized sheep erythrocytes (EAs) was effective when the EAs 
were incubated with normal human serum (NHS) but not when the EAs were incubated 
with C1q-depleted (C1q-dpl) serum (Fig. 18A). Supplementing C1q-dpl serum with C1q 
restored full hemolytic activity (Fig. 18A), demonstrating that under the conditions used, 
hemolysis of EAs is primarily the consequence of CP activation and that the presence of 
C1q is required for the activity. Factor B is a key protease in the activation of the AP. 
EAs hemolysis in factor B-depleted (fB-dpl) serum is indistinguishable from that in 
NHS (Figure 18A), suggesting that the AP has a minor (if any) effect on hemolysis 
under these experimental conditions. However, generation of C3b convertase (C4bC2a) 
as the result of CP activation may possibly initiate the AP. To exclude any involvement 
of the AP, I used fB-dpl serum in some experiments.  
Addition of purified recombinant His-tagged Cna31-344 to NHS or to fB-dpl serum 
prior to the addition of sensitized erythrocytes inhibited hemolysis of EAs in a dose-
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Figure 18 Cna31-344 inhibits activation of the CP 
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dependent manner (Figure 18B), demonstrating that Cna31-344 blocks the formation of the 
MAC on the erythrocytes surface. The inhibitory effect of Cna31-344 was somewhat more 
pronounced when fB-dpl serum was used compared to NHS, supporting the hypothesis 
that Cna inhibits the CP. Cna31-344 also inhibited hemolysis in C1q-dpl serum 
complemented with C1q (Figure 18C). 
Next, I determined the relative amounts of C4b generated and deposited on a 
microtiter plate coated with IgM as a read-out for CP activation. C4b deposition was 
increased with increasing concentrations of NHS. At a fixed concentration of NHS, pre-
incubation of the serum with Cna31-344 decreased C4b deposition, and the effect 
depended on the amount of added Cna (Figure 18D). In contrast to IgM coated surface, I 
did not observe C4b deposition on the Cna coated surface, suggesting that Cna did not 
by itself activate the CP. Thus the observed CP inhibition (Figure 18, C and D) is not 
due to a consumption of complement components. 
 
Cna mutants lost the ability to inhibit classical pathway activation  
I next evaluated the ability of the Cna mutants to inhibit activation of the CP. 
Compared with wild-type Cna, Cna mutants (QIE, ∆latch, Y175K, and ∆EAGTSS) that 
had a reduced affinity for C1q, showed a diminished ability to inhibit EAs hemolysis. 
The percentage of erythrocytes lysed in the presence of wild-type Cna (26%) was 
increased to 44%, 50%, 58% and 56% in the presence of mutants QIE, ∆latch, Y175K, 
and ∆EAGTSS, respectively (Figure 18E). The ability of these mutants to inhibit C4b 
generation and deposition was reduced in a similar manner (Figure 18F). These results 
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correlated the degree of inhibition of CP activation with the relative C1q-binding 
affinities (Fig. 17C, 17E, 18E and 18F).  
Taken together, our data strongly suggest that Cna31-344 interferes with activation 
of the classical complement pathway and the relative inhibitory activity on Cna mutants 
correlate with their relative collagen binding activity. 
 
Molecular bases for Cna dependent inhibition of the classical pathway 
Formation of the C1 complex is a prerequisite for activation of the CP. The 
C1r2C1s2 tetramers bind to the collagenous regions in C1q to form the C1 complex 
(Bally et al, 2009). Our results indicated that Cna31-344 also binds to the collagenous 
domain in C1q. I therefore asked if Cna31-344 could interfere with the interactions 
between C1r2C1s2 and C1q. Cna31-344 inhibited C1q from binding to C1r in a 
competition ELISA where wells coated with C1r were incubated with a constant amount 
of C1q and increasing concentrations of Cna31-344 (Figure 19A). Cna31-344 had a 
marginal inhibitory effect on C1q binding to immobilized C1s (Figure 19B). The Y175K 
mutant, that lost its affinity for C1q, did not affect the C1q-C1r or the C1q-C1s 
interactions (Figure 19, A and B). These results suggested that Cna interferes with the 
C1r-C1q interaction by binding to C1q.  
The majority of C1q in normal serum is present in the C1 complex (De Bracco & 
Manni, 1974). I therefore investigated if Cna31-344 could disassemble a preformed C1 
complex. Pull down assays were conducted using a monoclonal antibody against C1q 
and the composition of the pulled down C1 complex was evaluated using specific 
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antibodies against C1r or C1s. Strikingly, addition of soluble Cna31-344 to the C1 
complex significantly decreased the amount of C1r and C1s that was retained in the C1 
complex, whereas the amount of C1q pulled-down was similar to that in the control 
group (Figure 19C), suggesting that Cna displaced C1r and C1s from the C1 complex. 
Pre-incubation of the C1 complex with the Y175K mutant did not affect the amount of 
C1r and C1s in the pulled-down complex (Figure 19C). An anti-His antibody detected 
recombinant His-tagged Cna31-344 protein in the complex that was pulled down by the 
anti C1q antibody (Figure 19C), demonstrating that Cna31-344 indeed bound to C1q.  
I also investigated if surface-bound Cna31-344 is capable of displacing C1r and 
C1s from the C1 complex. Microtiter wells were coated with either IgM (Figure 19D) or 
Cna31-344 (Figure 19E) and incubated with increasing concentrations of the C1 
complex. The presence of C1q, C1r, and C1s within the bound complex was detected 
with specific antibodies. In IgM coated wells all three C1 components were successfully 
detected and the amount of C1q, C1r and C1s detected increased in parallel with the 
amount of complex added (Figure 19D). Isolated C1r and C1s had negligible IgM-
binding activity (data not shown), indicating that the detected C1r and C1s is part of an 
IgM-bound C1 complex. Intriguingly, C1q was the only C1 complex subunit that could 
be detected on the Cna31-344-coated surface, demonstrating that surface-bound Cna31-
344 also displaced C1r2C1s2 from the C1 complex (Figure 19E). Collectively, these 
data demonstrate that Cna31-344 binding to C1q interferes with the C1q interaction with 
C1r and results in dissociation of the C1 complex. 
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Figure 19 Molecular bases for Cna-dependent inhibition of 
the classical pathway 
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Recognition and binding to surface-bound antibodies by the C1 complex is 
required for initiation of the CP. I next investigated if Cna31-344 also affects the 
recognition of surface-bound antibodies by the C1 complex. This hypothesis was tested 
in ELISA-type binding experiments using IgM coated microtiter wells. Increasing 
concentration of Cna31-344 inhibited the C1 complex binding to the IgM-coated surface 
(Figure 19F). In contrast, Y175K, which does not bind C1q, did not interfere with the C1 
complex-IgM interactions (Figure 19F). Consistent with this finding, dose-dependent 
binding of the C1 complex to the IgM coated surface was significantly attenuated by 
addition of Cna31-344 (50 μM) (Figure 19G). The half-maximum binding concentration 
increased from 6 nM (control, in the absence of Cna31-344) to 94 nM (in the presence of 
Cna31-344), indicating a nearly 17-fold decrease in binding affinity. Addition of Y175K 
did not alter the binding kinetic of C1 complex to IgM and the kinetic was 
indistinguishable from that of the control (Figure 19G). These results demonstrated that 
Cna inhibits the C1 complex binding to the immune complex and that the activity is 
determined by the C1q-binding affinity. Interestingly, the influence of Cna on binding of 
isolated C1q to IgM was insignificant (Figure 19H). The fact that the C1 complex 
exhibits a higher affinity for immune complexes than does isolated C1q (data not shown) 
supports the idea that two distinct conformational states with different binding properties 
exist for C1q in these two conditions (Perkins, 1985) and our results indicate that Cna 
binding to the C1q subunit may stabilize the conformation of C1q that has a low affinity 
for immune complexes.   
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In summary, I demonstrated that Cna (and presumably other members of the 
Cna-like family of collagen-binding MSCRAMMs) inhibits activation of the CP by 
binding to C1q and interfering with the C1q-C1r interaction thereby disassembling and 
deactivating the C1 complex.   
 
Other Gram-positive collagen-binding MSCRAMMs bind C1q and block    
the classical pathway 
A number of Gram-positive bacteria express collagen-binding MSCRAMMs that 
have similar structural organizations (Figure 13) and show a high degree of sequence 
and structural similarities within the collagen binding segments. Cna from S. aureus is 
the prototype member of this family of collagen-binding MSCRAMMs that include Ace 
from Enterococcus faecalis (Liu et al, 2007), Acm from Enterococcus faecium 
(Nallapareddy et al, 2003), Cne from Streptococcus equi (Lannergard et al, 2003), and 
Cnm from Streptococcus mutans (Nakano et al, 2010) and others (Patti et al, 1994). To 
determine if these collagen-binding MSCARAMMs bind C1q and function as 
complement inhibitors, I first compared the collagen- and C1q-binding activities of 
purified recombinant proteins containing N1N2 domains of these MSCRAMMS (Table 
3). These proteins all bound to collagen and C1q in dose-dependent manners although 
they exhibited different binding capacities in the ELISA-type assays (Figure 20, A and 
B). Among them, Cna31-344 bound to collagen with the highest affinity, with half-
maximum binding observed at a concentration of 0.02 μM, whereas Ace32-367 showed 
minimal binding activity under the conditions used (Figure 20A). Binding of these 
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Figure 20 Structurally related collagen-binding MSCRAMMs  
bind to C1q and inhibit the CP activation. 
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proteins to C1q largely followed the relative binding activities for collagen type I (Figure 
20B). However, there were exceptions; Cne28-323 bound somewhat more effectively to 
C1q than Cna31-344 (Figure 20B) whereas the reverse was seen when collagen type I 
was targeted (Figure 20A). Ace32-367 showed noticeable binding to C1q (Fig. 5B) 
whereas Acm29-320 bound weaker to C1q (Fig. 5B) than to collagen type 1 (Figure 
20A) and was the worst C1q binder of the MSCRAMMs tested (Figure 20B). 
I next determined the effect of these collagen-binding MSCRAMMs on 
hemolysis and C4b deposition. Consistent with our observation for Cna31-344, all 
MSCRAMMs inhibited EAs hemolysis (Figure 20C) and C4b deposition (Figure 20D), 
and the extent of inhibition was directly related to their relative C1q-binding affinities, in 
which Cne28-323 shown the strongest and Acm29-320 showed the weakest inhibition 
(Figure 20, C and D). In summary, our results demonstrated that collagen-binding 
MSCRAMMs from Gram-positive bacteria are also inhibitors of the classical 
complement pathway. 
 
Discussion   
The Cna-related collagen-binding MSCRAMMs represent a growing family that 
currently includes almost 20 members from a variety of human and animal Gram-
positive (Kreikemeyer et al, 2005; Krishnan & Narayana, 2011; Patti et al, 1994; 
Sillanpaa et al, 2009; Xu et al, 2004a) and -negative pathogens (Fink et al, 2002; 
MacKichan et al, 2008; Patti et al, 1994; Wagner et al, 2007). I report that at least five 
members of this MSCRAMM family bind C1q and inhibit the CP of the complement 
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system. Cna31-344 appears to bind to the triple helix collagenous domains of C1q and a 
set of Cna mutants showed similar relative affinities for collagen and C1q. Cna interferes 
with the interaction of C1r with the collagenous “stems” of C1q. As a result the 
C1r2C1s2 tetramer cannot dock with C1q or, if Cna encounters a preformed C1 
complex, C1s and C1r are displaced resulting in a single isolated hexameric non-active 
C1q. It is likely that all members of the Cna family of collagen-binding MSCRAMMs 
inhibit the CP by the same molecular mechanism and there is a direct correlation 
between the individual MSCRAMM’s affinity for C1q and relative CP inhibitory 
activity. However, there is not a direct correlation between an individual MSCRAMM’s 
relative affinity for type 1 collagen and C1q, suggesting subtle differences in binding 
specificities.  
Cna is a proven virulence factor in several S. aureus infectious disease models, 
such as endocarditis (Hienz et al, 1996), osteomyelitis (Elasri et al, 2002; Johansson et 
al, 2001), keratitis (Rhem et al, 2000) and arthritis (Xu et al, 2004b). Similarly, Ace and 
Acm contribute to disease progression in experimental endocarditis (Nallapareddy et al, 
2008; Singh et al, 2010), while Cnm is critical for S. mutans to adhere to heart 
endothelial cells (Abranches et al, 2011) and is associated with hemorrhagic stroke 
(Nakano et al, 2011). It has been presumed that the Cna-like MSCRAMMs in these 
models act as adhesins and promote bacterial colonization of collagen in host tissues. 
Undoubtedly, Cna can function as an adhesin and mediate staphylococcal colonization 
of collagenous substrates (Patti et al, 1994). However, our finding that the Cna-like 
MSCRAMMs are inhibitors of complement activation points to an alternative 
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mechanism of action for these virulence factors. An immune evasion mechanism may 
explain some earlier results using an experimental arthritis model (Xu et al, 2004b), in 
which I showed that the expression of Cna did not contribute to the initial colonization 
of the tissue by S. aureus. Instead, expression of Cna on S. aureus elicited a more severe 
disease progression over a 28 day period. In the same context, Cna-like MSCRAMMs 
block the formation of the MAC (Figure 20C), the terminal effector function of the 
complement activation; it is therefore very likely that the generation of the inflammatory 
mediators (C3a, C5a) during the process of complement activation is also blocked by 
presence of these MSCRAMMs and subsequently neutrophil recruitment and 
phagocytosis could also be possibly inhibited. Future studies will address these 
questions.  
 Cna binds collagen by the “collagen-hug” mechanism. An initial interaction of 
Cna with collagen induces a redirection of the sub-domains in the binding region of the 
MSCRAMM allowing the N1-N2 domains to encompass the triple helix and “hug” the 
collagen monomer (Zong et al, 2005). The diameter of the “hole” formed by the N1-N2 
domains of Cna when complexed to a collagen triple helix peptide is about 15 Å, as 
calculated from the crystal structure (Zong et al, 2005). This space can accommodate 
only one monomeric collagen triple helix structure (diameter ~ 15Å) (Brodsky-Doyle et 
al, 1976; Chung et al, 2004). Thus Cna can only bind to collagen triple helix monomers 
but not to collagen fibers or fibrils. This property has recently been taken advantage of 
where investigators have used a fluorescently tagged form of Cna to detect monomeric 
collagen product during fibrosis (Chen et al, 2011). This specificity also limits the type 
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of collagenous tissue that can be targeted in Cna-dependent adhesion since collagen is 
primarily found in higher orders of fibrous super structures in healthy mature tissues. 
However, the collagenous “stems” of C1q are always available as monomeric triple helix 
structures. Hence, the ability of the Cna-like MSCRAMMs to bind to C1q and inactivate 
the CP may be an important component of the virulence potential of these molecules. 
Surface-bound Cna interacts with C1q in solution with high affinity (Fig. 17D), 
which may be due to the ability of one C1q molecule to interact with multiple 
MSCRAMMs. This represents the most direct and effective way in which the Cna-like 
MSCRAMMs encounters and inactivates the CP. However, surface anchored 
MSCRAMMs such as Ace can be cleaved by protease (McAleese et al, 2001; McGavin 
et al, 1997; Pinkston et al, 2011) and generated MSCRAMM fragments released into the 
environment may retain their ligand binding activity. This observation raises the 
possibility that cell-wall anchored MSCRAMMs may not only function as surface-bound 
virulence factors but also as a reservoir for the release of biologically active compounds. 
Thus, the release of C1q-binding fragments of Cna-like MSCRAMMs would allow these 
fragments to inhibit the CP away from the bacterial colony and could result in a more 
systemic inhibition of the complement system.  
Earlier SPR analyses of Cna binding to type 1 collagen demonstrated that the 
collagen molecule contains multiple classes of binding sites with different affinities for 
the MSCRAMM (Rich et al, 1999a). Thus, the high affinity Cna binding sites in type 1 
collagen are likely composed of different sequences than the Cna binding sites in C1q, 
which exhibit moderate affinity for the MSCRAMM. Whereas Cna binds with much 
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higher affinity to type I collagen compared with C1q, some other members of the Cna-
like MSCRAMM family studied do not differ in their binding to collagen and C1q, for 
example Cne. These observations suggest that, although the different members of the 
Cna-like family of MSCRAMMs have similar sequences and structural organization, 
they have evolved to target different triple helix motifs with different affinities.   
Previous studies suggest that C1q is a flexible molecule that undergoes 
conformational changes upon binding to the C1r2C1s2 tetramer and antibodies on the 
bacterial surface (Perkins, 1985; Schumaker et al, 1981). Our data revealed that the C1 
complex and isolated C1q differ in their affinities for immobilized IgM (data not 
shown), supporting the existence of two distinct C1q conformations (Schumaker et al, 
1981). This result also demonstrates that the C1 complex form of C1q is in a state that is 
favorable for antibody-binding, whereas the isolated C1q has a relatively unfavorable 
binding conformation. The ability of Cna31-344 to displace C1r2C1s2 from the C1 
complex (Figure 19, C-E) and to inhibit C1 complex binding to surface-bound antibodies 
(Figure 19, F and G) suggests that binding of Cna31-344 to C1q stabilizes the low 
affinity conformation of the complement component. The observation that Cna31-344 
did not affect the interaction of isolated C1q with antibodies supports this hypothesis. 
In summary, our data provide evidence for the first time that Cna-like collagen-
binding MSCRAMMs are not only adhesins but also are potential complement 
inhibitors. The dual functions of MSCRAMMs illustrate the elaborated strategies 
evolved by pathogenic microorganisms to adhere to and colonize host tissues and evade 
the host defense systems. The molecular mechanism uncovered in this study of how 
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Cna-like MSCRAMMs interact with C1q and disrupt the complement activation may 
represent a global mechanism used by collagen-binding MSCRAMMs from different 
bacterial species.  
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CHAPTER IV 
BIOLOGICAL SIGNIFICANCE OF THE CNA-C1Q INTERACTION IN VIVO 
 
Introduction  
Septic arthritis is a disease caused by the invasion of infectious agents e.g., 
bacteria on a joint, which interact with host immune system, and result in the production 
of a large amount of inflammation (Wang et al, 2009). S.aureus is one of the most 
common bacteria isolated from clinical septic arthritis (Shirtliff & Mader, 2002). It is 
believed that the collagen-binding MSCRAMM from S.aureus-Cna is a critical virulence 
factor in experimental mouse model of septic arthritis, based on its collagen binding 
activity (Patti et al, 1994; Xu et al, 2004b). However, the detailed molecular mechanism 
on the roles of Cna in pathogenesis of arthritis is not well characterized.   
A previous structural study in our lab demonstrated that Cna only binds collagen 
triple helixes, but not collagen fibril (Zong et al, 2005).  It is well known that the 
majority of the collagen in the healthy human or mouse exists in the form of collagen 
fibril, which provides few binding sites for Cna. This may be the potential explanation 
for why Cna doesn’t contribute to the initial colonization in S.aureus arthritis model (Xu 
et al, 2004b). These data also indicated that besides collagen binding, Cna might also 
have other functions during the early stage of infection, which might contribute to the 
pathogenesis of septic arthritis 
  In chapter III, I have already demonstrated that Cna interacts with C1q and 
inhibits CP. C1q is a multi-functional molecule that also contributes to other immune 
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functions such as the clearance of apoptotic cells via direct/indirect interaction or 
classical pathway activation (Nayak et al, 2010). Failure to clean apoptotic cells in 
human body will release dangerous signals such as autoimmune peptides, resulting in 
inflammation and immune disease, such as arthritis. Therefore, I proposed that binding 
of Cna to C1q contributes to the pathogenesis of S.aureus infectious disease.  
In this part of the study, I utilized the C1q knockout mice to investigate the 
biological significance of C1q-Cna interactions in S.aureus infections. I performed the 
S.aureus arthritis model and sepsis model by using S.aureus clinical Cna positive strain 
Phillips and its cna mutant PH100 (Patti et al, 1994). The results provided, for the first 
time, direct evidences that Cna enhances S.aureus virulence by binding to C1q.  
 
Results 
Cna is not a human-specific complement inhibitor  
In chapter III, I demonstrated that Cna inhibits the human CP by interacting with 
collagen-like domain of C1q. To investigate whether Cna is a human specific inhibitor, I 
examined the Cna- mouse C1q interaction and effects of Cna on mouse CP by analyzing 
C4b depositions. In microtiter wells, the immobilized recombinant Cna31-344 bound to 
human C1q or mouse C1q in the human normal serum or mouse normal serum 
respectively, compared to the control, which used the C1q-Dpl serum from human or 
mouse (Figure 21A). This observation suggested that Cna also interacts with mouse C1q. 
Moreover, to evaluate the effect of Cna on mouse CP, I quantitated the deposition of 
mouse C4b on mouse IgM coated surfaces. Not surprisingly, Cna, as well as the 
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Figure 21Cna binds mouse C1q 
and inhibit mouse CP 
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monoclonal anti-mouse C1q antibody, strongly inhibited mouse C4b depositions (Figure 
21B). In contrast, CnaY175K, which neither interacts with human C1q nor inhibits human 
CP, didn’t interfere with mouse C4b deposition, compared to the control (Figure 21B). 
These data suggested that Cna doesn’t exclusively inhibit human CP. However, it at least 
interacts with mouse C1q and blocks the mouse CP. 
 
Cna-C1q interaction enhances S.aureus infection  
It is well known that the weight loss during infection is usually related to the 
severity of the disease (Xu et al, 2004b). By exploiting the biological significance of the 
Cna-C1q interaction in vivo, I compared the weight loss in wild type mice and C1q 
knockout mice challenged by Cna positive strain Phillips or Phillips cna knockout strain 
PH100 through tail vein IV injection respectively for two weeks. All mice challenged 
with the bacteria reduced the body weight. However, both wild type mice and C1q 
knockout mice infected with the Phillips stain reduced weight more rapidly than those of 
mice infected with PH100 (Figure 22, A and B). These data demonstrated that Cna is a 
critical virulence factor in the S.aureus infection, which validated previous animal 
experiment results published by our lab (Patti et al, 1994; Xu et al, 2004b). Surprisingly 
and interestingly, C1q knockout mice lost much less weight than that of wild type mice 
in both groups challenged by either Phillips strain or PH100 (Figure 22, A and B).  In the 
experimental group infected with Phillips strain, 12 out of 15 wild type mice lost over 
30% of weight at day 7, while none of the C1q knockout mice lost more than 30% of 
weight (Figure 22A). While in the PH100 infection group, none of mice (wild type mice 
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Figure 22 Binding of Cna to 
mouse C1q contributes S.aureus 
infections 
 75 
 
and C1q knockout mice) lost over 30% of weight (Figure 22B). In order to further 
interpret the weight loss data, I used 30% of weight loss as the cut-off value to plot the 
survival curve, including mice that died (Figure 22, C and D). The C1q knockout mice 
showed significantly more resistance to Phillips strain infection, compared to the wild 
type mice infected with Phillips strain (Figure 22C), whereas there was no significance 
in the survival rates between wild type mice and C1q knockout mice infected with 
PH100 (Figure 22D). These data suggested that Cna-C1q interaction plays a critical role 
in S.aureus virulence.   
To further investigate the role of this interaction in vivo, I examined the bacterial 
burdens in blood and various organs at 24 hours after infection. In blood, S.aureus was 
hardly detected in either wild type or C1q knockout mice infected with Phillips strain or 
PH100 strain. In contrast, I detected large amounts of S.aureus in organs, such as liver, 
heart, spleen and kidney. These results suggested that S.aureus can be easily cleared 
from blood, be disseminated to and colonize within different organs immediately upon 
infection. Comparing the bacterial counts between S.aureus Phillips strain and PH100 in 
WT mice, 6 mice challenged with S. aureus Phillips had significantly more viable S. 
aureus cells isolated from the heart, kidney and liver, than the mice infected with PH100 
strain (Figure 23). Moreover, in kidney and liver from mice infected with Phillips strain, 
C1q knockout mice exhibited significantly reduced bacterial burden, compared to the 
WT mice. However, there is no dramatic difference in bacterial burden in kidney and 
liver between WT mice and C1q knockout mice infected with PH100 (Figure 23). 
Similarly, I also found that C1q knockout mice infected with Phillips strain showed 
 76 
 
Figure 23 Bacterial burden in the 
blood and different organs at day 
1 after infection 
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Figure 24 Bacterial burden in 
kidney and liver at day 6.5 after 
infection 
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dramatically reduced bacterial counts in liver than those of the infected WT mice at day 
6.5 (Figure 24). These data further indicated that Cna-C1q interaction enhances S.aureus 
infection and dissemination.  
 
Discussion  
Cna is a well-known virulence factor in several S. aureus infectious disease 
models such as endocarditis (Hienz et al, 1996), osteomyelitis (Elasri et al, 2002; 
Johansson et al, 2001), keratitis (Rhem et al, 2000) and arthritis (Xu et al, 2004b) and it 
is believed that the collagen-binding activity of Cna is a critical determinant for these 
diseases. Here I report that besides collagen binding, the binding of Cna to C1q may also 
contribute to the pathogenesis of S.aureus infectious diseases. Specifically, our S.aureus 
infection mouse model demonstrates that Cna-C1q interaction enhances S.aureus 
virulence, dissemination to and colonization within the liver in mice. 
C1q is highly conserved among different species. The comparison of amino acids 
of each polypeptide chain between human and mouse C1q showed a high similarity 
(over 80%) in sequence. Not surprisingly, Cna also interacts with mouse C1q and 
inhibits mouse CP C4b depositions, while CnaY175K doesn’t inhibit c4b depositions 
(Figure 21). I also believed that the binding mechanisms and the inhibition mechanisms 
are similar between human and mouse.   
 It is reported that C1q itself and the CP play an important role in the recognition 
and the clearance of microbes and their deficiencies significantly facilitate bacterial 
infections (Schejbel et al, 2011). Therefore, based on the above studies, C1q knockout 
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mice should be more susceptible to bacterial infections, such as Salmonella infection 
(Warren et al, 2002). Surprisingly, our data show that C1q knockout mice are more 
resistant to Cna positive S.aureus Phillips infection. During this infection model, only 
two WT mice and one C1q knockout mice “really died” after Cna positive S.arueus 
infections. Most of the mice challenged with Cna positive bacteria continued to lose the 
body weight to over 30%. Even though the mice were not in a good condition, they did 
not die. This phenomenon is dramatically different from that of the S.aureus ClfA sepsis 
model performed in our lab previously (unpublished data), where most of mice died 
quickly. Because of higher bacterial load in the liver from WT mice infected with Cna 
positive S.aureus, I believe that the body weight loss of mice infected with Cna positive 
S.aureus may be presumably caused by the failure of liver functions, which needs further 
investigations. More surprisingly, the WT mice infected with Cna negative S.aureus 
(PH100) also experienced significantly more body weight loss than that of the C1q 
knockout mice, despite that it had much lower significance level compared to the weight 
loss difference between WT mice and C1q knockout mice infected with Cna-positive 
S.aureus (Figure 22 A and B). Therefore, I proposed that PH100 might secrete another 
C1q receptor. We used the supernatant of PH100 overnight culture media to pass 
through immobilized C1q sensor chip and observed the binding responses (Figure 25). 
Further experiments are needed to identify this novel C1q receptor.  
Combining these in vitro and in vivo data, I believe that Cna might have other 
biological functions, besides acting as a collagen adhesin and complement inhibitor.  
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Figure 25 Binding of component(s) from the 
supernatant of PH100 culture medium to C1q 
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The most recent reports published from our lab showed that S.aureus utilizes Efb to form 
the fibrinogen “shield”, in order to inhibit phagocytosis (Ko et al, 2013). It is implied 
that membrane-bound Cna might have similar functions. In the blood, membrane-bound 
Cna or soluble cleaved Cna interacts with C1q and inhibits the CP. Meanwhile 
membrane-bound Cna will hijack C1q to form the C1q “shield” to block the immune 
system recognition. Furthermore, our bacteria count data demonstrated that this 
interaction benefits S.aureus dissemination and liver colonization (Figure 23 and 24). It 
is well known that the epithelial cells of liver and many immune cells located in the liver 
express C1q receptors. These “coated C1q” on bacterial surface might also interact with 
C1q receptors on the surface of immune cells and help S.aureus dissemination to and 
colonization of liver. 
 Aside from the classical pathway activation, C1q also has multiple functions, 
such as clearance of the apoptotic cell (Nayak et al, 2010). Failure to clear apoptotic 
cells will lead to inflammation and autoimmunity. Both osteomyelitis and septic arthritis 
are diseases of inflammation. It is reported that C1q is associated with the pathogenesis 
of arthritis (Olsen et al, 1991). On the other hand, Cna from S.aureus is a virulence 
factor in experimental animal models of osteomyelitis and arthritis. Therefore, I 
hypothesized that Cna-C1q interaction contributes to the S.aureus pathogenesis, 
especially septic arthritis. To test this hypothesis, I evaluated this interaction in S.aureus 
arthritis model by using C1q knockout mice. Unfortunately I didn’t see any clinical signs 
of arthritis in both WT mice and C1q knockout mice infected with Cna positive S.aureus 
Phillips strain. This could mainly be due to that the mouse strain (C1q knockout mice are 
 82 
 
in a C57BL/6 background) I used is not genetically susceptible to the development of 
arthritis induced by S.aureus (Bremell et al, 1991). In order to continue the study on the 
role of C1q-Cna interaction in arthritis model, C1q knockout mice in Swiss or BalbC 
strain background will be used, which is our plan for future studies. 
Overall, I have shown that Cna-C1q interaction enhances S.aureus infection and 
dissemination. These data also indicated that Cna is not only a complement inhibitor for 
classical pathway activation, but also utilizes C1q to evade immune system and help 
S.aureus dissemination. These findings reveal the complicated roles of Cna in S.aureus 
pathogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 83 
 
CHAPTER V 
COMPLEMENT EVAVSION BY BBP (SDRE) 
 
Introduction  
The complement system, a major component of the innate immunity, consists of 
different proteins and glycoproteins that interact with one another leading to cascades of 
immune response through three distinct pathways. All of these pathways converge to C3 
convertase which cleavages C3 into C3a and C3b. There are two different kinds of C3 
convertases: C4bC2a and C3bBb. In the CP and the LP, active serine proteases (C1s or 
MASP2) cleave C4 and C2 to form C4bC2a. Whereas in the AP, the deposited C3b 
fragment interacts with factor B to form C3bB complex. Binding of factor D to C3bB 
complex activates factor D, which can cleave factor B and then release the small 
fragment Ba. The remaining fragment C3bBb is a functional C3 convertase. Since C3 
convertase plays an essential role in the complement activation, numerous pathogenic 
bacteria employ distinct molecules to target C3 converses, especially C3b.  As 
successful pathogenic bacteria, S.aureus also utilizes various proteins, most of which are 
secreted proteins, such as Efb and SCIN, to interfere with the functions of C3 or C3b. 
Recently, it is reported that the Fg-binding MSCRAMMs from S.aureus - SdrE 
and Bbp bind to the complement regulators factor H and C4BP to inhibit PMN killing 
(Hair et al, 2013; Sharp et al, 2012). Bbp and SdrE are allelic variants (Hair et al, 2013), 
both of which have similar domain organizations containing N-terminal Fg-binding 
domain A followed by three B repeats and Ser-Asp (SD) dipeptide repeats. The Fg-
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binding domain only contains N2N3 subdomains, to which SdrE and Bbp exhibit around 
67% amino acid sequence similarity (Francis, 2013). However, in the N1 subdomain and 
B repeats, 95% sequence similarity is found between Bbp and SdrE. Due to the 
difference in the Fg-binding domain, SdrE and Bbp show different Fg binding specificity 
for different species (Francis, 2013). Bbp is more human specific, while SdrE has a weak 
affinity to human Fg, despite of relatively higher affinity to animal Fg, such as that of 
cow, pig, dog, sheep and cat.  
In this study, I report that Bbp (SdrE) inhibits all three complement pathways and 
only inhibits C3b depositions of the AP via binding to C3b and interfering with the 
formation of C3b convertase.  
 
Results 
Bbp and SdrE inhibit complement activations 
All complement pathways play an important role in anti-bacterial infection. In 
order to further evaluate the effect of Bbp or SdrE on each complement pathway, I 
investigated whether Bbp or SdrE inhibits the CP and the AP by using hemolysis assays 
and the LP using the ELISA-type assay where I quantitated the deposition of C5b-9 on 
mannan coated surfaces. Hemolysis of antibody-sensitized sheep erythrocytes (EAs) is 
used to analyze the CP. When the EAs were incubated with NHS, hemolysis of EAs was 
effective (Figure 26, A and F). The addition of purified recombinant His-tagged and 
truncated Bbp and SdrE proteins containing N2N3 to the NHS, prior to the addition of 
sensitized erythrocytes, inhibited the hemolysis of EAs by around 60% at the 
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Figure 26 . SdrE and Bbp inhibit 
all three complement pathway 
activations 
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concentration of 150 µM. This result demonstrated that Bbp and SdrE block the 
formation of MAC on the erythrocyte surface. Since the generation of C3b convertase 
(C4bC2a) in the CP activation might possibly facilitate activation of the AP, I used fB-
dpl serum without AP activity to exclusively analyze activation of the CP. The effect of 
Bbp and SdrE on hemolysis mediated by fB-dpl serum was similar to the NHS (Figure 
26B). It is reported that Bbp/SdrE interacts with factor H and inhibits PMN killing 
(Sharp et al, 2012). To exclude the possibility that the binding of Bbp/SdrE to factor H 
inhibits complement activation, I tested the hemolysis by using fH-dpl serum and also 
got similar inhibition results as using NHS (Figure 26C), which indicates that Bbp/SdrE- 
factor H interaction doesn’t affect the inhibition of hemolysis mediated by CP. Similarly, 
in the AP, hemolysis of rabbit erythrocytes mediated by NHS was also blocked by Bbp 
and SdrE at the concentration of 150 µM (Figure 26D). To show the specificity, I also 
performed dose-dependent inhibition assays and observed that Bbp and SdrE inhibited 
hemolysis in dose-dependent manner for both the CP and the AP. The reduction was 
statistically significant at protein concentration of 50 µM and above (Figure 26, E and 
F). The hemolysis assay cannot be used for the LP. To evaluate the effect of Bbp and 
SdrE on the LP, I detected the deposited MAC (C5b-9) by ELISA. Bbp and SdrE also 
inhibited the MAC deposition by over 60% at the concentration of 150 µM (Figure 26 
G).  
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Figure 27 Bbp and SdrE only 
interfere C3b depositions of AP 
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Bbp and SdrE inhibit C3b deposition of the AP, but not the LP and the CP  
My data demonstrated that Bbp and SdrE inhibit all three complement pathways. 
To narrow down Bbp and SdrE’s target(s), I evaluated the complement activation by 
detecting the deposited C3b. The relative amount of C3b generated and deposited on a 
microtiter plate coated with IgM, mannan and LPS as a read-out for the CP, the LP and 
the AP activation respectively. At a fixed concentration of NHS, pre-incubation of the 
serum with Bbp and SdrE only interfered with the C3b deposition of the AP (Figure 
27B), whereas the C3b depositions of the CP and the LP were not affected (Figure 27 A 
and C). 
 
Bbp or SdrE interacts with C3, C3b and C3c  
The observed inhibition of all three complement pathways and the AP C3b 
deposition mediated by Bbp and SdrE raised the possibility that Bbp and SdrE could act 
either on C3 or C3 small fragments, which are critical complement components in all 
complement pathways. To evaluate the direct interaction between C3 or C3b and Bbp or 
SdrE, I detected the C3b binding by using ELSIA and SPR binding assay. Bbp bound 
human Fg or C3b coated in microtiter wells in a dose dependent manner and exhibited 
saturation kinetics (Figure 28). While Bbp has much higher affinity to human Fg, 
compared to C3b binding. The half maximal bindings are 0.23 µM and 4.1 µM, 
respectively. ClfB is another fg-binding MSCRAMM from S.aureus, which doesn’t bind 
to immobilized C3b at all concentrations tested (Figure 28).   
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Figure 28 Binding of Bbp to 
immolibzed C3b. 
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Figure 29 Biacore analysis of the interactions between C3 or C3 small components 
and the recombinant Bbp or SdrE proteins 
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Table 7 Kinetic profiles of the direct interaction between Bbp or SdrE and C3, C3b 
or C3c 
Table 7. Kinetic profiles of the direct interaction between Bbp or SdrE and C3, C3b 
or C3c 
Bbp/SdrE Ligands  ka1(1/Ms) kd1(1/s) ka2(1/s) kd2(1/s) KD
app   
(µM) 
 C3 1.25×10
3
 2.27×10-
2
 6.76×10-
3
 1.06×10
-3
 2.5 
Bbp C3b 2.11×10
3
 2.02×10-
2
 3.34×10-
3
 6.34×10
-3
 6.3 
 C3c 2.23×10
3
 1.94×10-
2
 3.01×10-
3
 4.1×10
-3
 5.0 
       
 C3 1.75×10
3
 6.21×10-
2
 2.44×10-
2
 1.24×10
-3
 1.7 
SdrE C3b 3×10
3
 3.28×10-
2
 6.75×10-
3
 6.58×10
-3
 5.4 
 C3c 1.44×10
3
 2.03×10-
2
 2.86×10-
3
 1.82×10
-3
 5.6 
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SPR analyses using C3, C3b, C3c and C3d immobilized on BIA-core CM5 chips 
were performed to further corroborate the interactions between Bbp or sdrE and C3 or  
C3 small components. Two-fold dilutions of the recombinant protein Bbp and SdrE 
(0.05 -25 µM) were run over a sensor chip containing immobilized C3 and C3b (Figure 
29 A-D).  Recombinant Bbp bound to immobilized C3b in dose-dependent manner with 
an affinity that appears to be substantially lower than that of C3 binding due to fast 
dissociation rates (Figure 29, A and C). The apparent KD for C3 and C3b are 2.5 µM and 
6.3 µM respectively.   
To further map the binding sites for Bbp on C3b, the recombinant Bbp was run 
through the immobilized C3c and C3d senor chips. C3c is a large fragment of C3b, both 
of which interacted with Bbp with similar affinities (Figure 29 E and G). While Bbp 
weakly bound to immobilized C3d (Figure 29 E). These data demonstrated that the Bbp 
binding site is located with the C3c fragment, instead of the C3d of C3. Similarly, 
compared to Bbp binding, SdrE with weaker affinity to human Fg (Francis, 2013), had 
the same binding patterns and the affinities to C3, as well as to its small fragments such 
as C3b and C3c with lower binding responses (Figure 29 B, D, F and G and Table 7).    
 
Bbp doesn’t compete with the binding of factor B and factor H to C3b  
Previous observations demonstrated that factor B bound to partial C3c fragment 
of C3b and factor H competes with Bb for C3b binding (Forneris et al, 2010; Wu et al, 
2009). Therefore I asked whether Bbp, factor B and factor H share the same binding 
sites on C3b. To achieve this goal, a fixed concentration of the respective factor B or 
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Figure 30 Bbp doesn’t share 
binding sites on C3b with factor 
B or factor H 
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factor H was mixed with Bbp and injected onto immobilized C3b sensor chip. If Bbp, 
factor B or factor H bind to C3b independently, the response of Biacore can be additive. 
In the case of factor B, the subtraction of the pure factor B response from the response of 
factor B and Bbp mixture revealed a similar binding response as that of pure Bbp (figure 
30 A), indicating that Bbp and factor B bind different areas on C3c. Since Biacore 
binding data shown in Figure 30B demonstrated that Bbp doesn’t interact with factor B, 
co-infection of Bbp and factor B onto immobilized C3b sensor chip also revealed that 
Bbp and factor B bound to different areas of C3b to form a Bbp-C3b-factor B complex 
(Figure 30 C). For the factor H binding, I got similar results, but due to the weak 
interaction between Bbp and factor H (Sharp et al, 2012), the response of the subtracted 
curve (fH+Bbp-Bbp) is a little bit higher than that of pure factor H (Figure 30 D).  
  
Bbp prevents the assembly of C3b convertase  
 Our data suggested that Bbp could inhibit the AP C3b deposition, but it doesn’t 
inhibit the C3b-facotor B interaction. Thus Bbp might affect the assembly of C3b 
convertase.  Previous reports demonstrated that the formation of C3b convertase can be 
detected by Biacore assay directly (Chen et al, 2010; Ricklin et al, 2009).  In the 
immobilized C3b sensor chip, the C3 convertase was formed when a mixture of factor B 
and factor D were run over the sensor chip and a very stable complex with a notably 
slow dissociation rate was detected (Figure 31A). The pre-incubation of Bbp with factor 
B/factor D mixture slowed down and reduced C3 convertase formation (Figure 31 A).  
Based on the binding of Bbp to the C3b sensor chip, I subtracted the Bbp response from 
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the responses of the mixtures, in order to obtain the responses of pure factor B and D in 
the presence of Bbp. Not surprisingly, the rate of the complex formation was 
significantly decreased, compared to the responses of pure factor B and D (Figure 31A).  
Since Bbp doesn’t inhibit the binding of factor B to C3b, but blocks the 
formation of C3bBb, I then hypothesized that Bbp affects the cleavage of factor B. In 
order to analyze the protease activity, I used the fact that complement factor P binds 
strongly to C3bBb (C3 convertase) but weakly to C3b and C3bfB (Hourcade, 2006). 
Indeed, after the factor P sensor chip was injected with C3b, a mixture of C3b and factor 
B or a mixture of C3b, factor B and factor D respectively, I only detected minimal 
response from C3b, the mixture of C3b and factor B bound to the factor P-coated surface 
(less or around 150RUs). In contrast, a mixture of C3b, factor B and factor D resulted in 
a substantial increase in signal to around 800 RUs which is more than 5 times higher 
than the response of the mixture of C3b and factor B or pure C3b (Figure 31B). These 
data demonstrated that binding responses from C3bBb, C3bB and C3b on immobilized 
factor P sensor surface are distinct and the response of C3bBb also indicates the 
cleavage of factor B. However, in the presence of various concentrations of recombinant 
Bbp, the binding response of a mixture of C3b, factor B and factor D decreased (Figure 
31C), suggesting that Bbp inhibits the formation of C3 convertase by interfering with the 
cleavage of factor B.    
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Figure 31 The assembly of C3 
convertase on an immobilized 
C3b  or factor P biosensor 
surface. 
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 Discussion 
As a successful pathogenic bacterium, S. aureus has evolved several strategies to 
evade or invade the host immune system, including the complement activation pathway.  
S.aureus expresses several well-known secreted complement inhibitors such as SCIN, 
Efb and Ecb, most of which target the C3b or C3 convertase. In this study, I identified 
two potential complement inhibitors that target C3b from S.aureus cell wall proteins: 
SdrE and Bbp. Specifically, the binding of Bbp or SdrE to C3c fragment of C3b inhibits 
the formation of AP C3 convertase by interfering with the cleavage of factor B.  
Both Bbp and SdrE belong to the Sdr family, composed of structurally related 
cell wall-associated proteins. Actually they are allelic variants (Hair et al, 2013{Francis, 
2013 #1535)}, both of which have similar domain architectures and share around 87% 
amino acid sequence in common. Most important thing is that the two genes occur in the 
same location of the core genome of S. aureus, but are found together in less than 1% of 
S. aureus isolates (Francis, 2013). Previous studies showed that Bbp specifically binds to 
human Fg Aα chain (Vazquez et al, 2011), whereas SdrE binds not only the same area 
with much lower affinity to human Fg, but also to some animal Fg such as bovine, cow, 
dog, sheep and cat (Francis, 2013). Surprisingly, the binding affinities of SdrE to human 
C3 or C3 small components are similar, with little lower binding response than that to 
the Bbp. It is very interesting to test whether theses interactions are also human specific.  
Besides Fg binding activity, recent studies showed that Bbp and SdrE interact 
with complement regulators factor H and C4BP, leading to the inhibition of 
phagocytosis killing (Hair et al, 2013; Sharp et al, 2012). Our lab also confirmed the 
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weak factor H-Bbp/SdrE interaction using SPR assays (Francis, 2013), which is also 
corroborated by Figure 30D. However, Bbp and SdrE inhibit the hemolysis assay 
mediated by factor H depleted serum, suggesting that the binding of factor H is not the 
major contribution to these complement inhibitions. I also believe that the inhibition of 
neutrophil killing mediated by SdrE/Bbp is also associated with C3b binding. Further 
experiments are needed to confirm this hypothesis and the analysis of Bbp or SdrE 
binding to different complement components simultaneously will also need to be 
investigated.  
In the AP, C3 is cleaved by C3 convertase C3bBb into C3a and C3b. This 
cleavage induces large conformational changes, which expose some critical residues for 
factor B binding (Schuster et al, 2008). Whereas the conversion from C3b to C3c 
mediated by factor I and co-factors only induces slight conformational changes (Garcia 
et al, 2010). This might explain why the binding of Bbp or SdrE to C3 has much slower 
dissociation rate than that of the C3b or the C3c binding. To further investigate these 
interactions, I immobilized Bbp on the senor chip to mimic the surface anchored protein, 
but unfortunately, I didn’t observe any binding responses. The possible explanation is 
that surface-immobilized Bbp may be disrupted by an inactivation during the random 
immobilization, which was previously observed in other S.aureus proteins (Ricklin et al, 
2009). 
The observation that Bbp or SdrE bound both immobilized C3b and C3c with 
similar affinity and response, but not C3d indicates that the binding sites must be located 
at the C3c fragment of C3b. It is well known that factor B and factor H share some 
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binding sites on C3c (Chen et al, 2010; Forneris et al, 2010). I therefore investigated 
whether the potential binding of Bbp to C3b would interfere with the activity of factor B 
and factor H. However, neither factor was substantially inhibited by Bbp on binding to 
C3b. Interestingly, I found that the effect of Bbp on the assembly of C3 convertase is 
striking. Preincubation of Bbp with a mixture of factor B and factor D decreased the 
assembly rate of the C3 convertase on the immobilized C3b sensor chip (Figure 31 A), 
due to the inhibition of the cleavage of factor B (Figure 31C). As a consequence, I 
confirmed that Bbp interferes with the formation of C3 convertase at a molecular level. 
In summary, my data provide evidence for the first time for direct interaction of 
Bbp and SdrE with C3b and their inhibition of the AP C3convetase formation by 
interfering with the cleavage of factor B. The various functions of Bbp or SdrE illustrate 
the elaborated strategies evolved by pathogenic microorganisms to adhere to and 
colonize within the host tissues and evade the host defense systems. The molecular 
mechanism described in this study may also benefit the development of potential anti-
complement treatments for other various immune diseases. 
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CHAPTER VI 
SUMMARY AND FURTURE DIRECTIONS 
 
Summary 
MMSCRAMs and SERAMs are widely expressed by different pathogenic 
bacteria. It is interesting that most of them have multiple ligands, in order to execute 
versatile functions. In light of our data, I demonstrated that Cna inhibits the CP by 
interacting with the collagen-like domain of C1q, while Bbp or SdrE inhibits all three 
complement pathways. All these studies exploited the novel functions of MSCRAMMs, 
which were previously implicated only as adhesion molecules with the role of mediating 
bacteria attachment to the host. Our study advances the knowledge on the role of 
membrane-bound proteins of bacteria as immune evasion molecules and hopefully will 
shed light on the discovery of more effective therapeutic strategies against S. aureus 
infections. Moreover, the data from this work may benefit the development of potential 
anti-complement treatments for other various immune diseases. 
 
Future directions 
Cna inhibits C4b deposition on bacterial surface 
I already showed solid in vitro data that Cna inhibits the classical pathway 
activation by interacting with C1q. However, most of my data are created using 
recombinant Cna. Therefore, I would like to see what could happen on the bacterial 
surface with Cna expression. One potential experiment is to detect C4b deposition on 
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bacterial surface. I didn’t see significant difference using S.aureus strain, which could be 
due to other known or unknown complement inhibitors form S.aureus. To exclusively 
analyze the function of Cna, I need to construct nonpathogenic bacteria without any 
known complement inhibitors to stably express Cna. Lactococcus lactis is a Gram-
positive bacterium without identified virulence factors. In the previous study in our lab, 
L.lactis has been widely used to express Fg-binding MSCRAMMs such Bbp and ClfA. 
Therefore, I could construct Cna –expressing L.lactis and use it to perform the bacterial 
C4b deposition assays.  
 
Cna inhibits complement-medicated phagocytosis 
MAC formation on the bacterial surface is one strategy for complement system 
to kill microbes, except for Gram-positive bacteria, due to the thick cell wall. However, 
complement-medicated phagocytosis plays a crucial role against Gram-positive bacteria, 
especially S.aureus.  Cna inhibits the C4b and C3b deposition of the CP, which raises 
the possibility that Cna interferes with the complement-medicated phagocytosis. I will 
make use of Cna-expressing L.lactis strain to analyze the role of Cna in the complement-
medicated phagocytosis 
 
Cna-C1q interaction plays a role in S.aureus infection in vivo  
Preliminary in vivo data showed that Cna-C1q interaction enhances S.aureus 
colonization in liver at day 1 and 6.5 but the biological significance for bacteria 
accumulation in the liver remains unclear. Why Cna-C1q interaction enhances S.aureus 
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colonization in the liver also needs further investigation. While these questions only hint 
at the possibility that liver endothelial cells and microphages could express some 
complement receptors such as C1q receptors, which might trap S.aureus within the liver. 
To test this hypothesis, I could use liver cell lines to test whether C1q-Cna interaction 
mediates S.aureus adhesion and invasion to the liver cells.  
 
Bbp/SdrE inhibits CP and LP 
My data showed that Bbp or SdrE inhibits all three complement pathways, but 
they didn’t block C3b deposition of the CP and LP . In the CP and LP, C3 convertase 
(C4bC2a) will interact with C3b to form C5 convertase.  It is possible that the binding of 
Bbp /SdrE to C3b inhibits the assembly of C5 convertase.  
 
Bbp or SdrE interacts with C5 
Besides C3 or C3 small components binding, I also found that Bbp and SdrE 
bind to immobilized C5 using SPR binding assays. Two-fold dilutions of recombinant 
protein Bbp and SdrE (0.05 -25 µM) were run over a BIA–core chip containing 
immobilized C5 (Figure 32 A and B). Recombinant Bbp and SdrE bound to immobilized 
C5 in dose-dependent manner with an affinity that appeared to be substantially lower 
than that of C3 binding due to a slower dissociation rate (Figure 32, A and B) . The 
apparent KD for binding of Bbp and SdrE to C5 were 10.4 µM and 8.3 µM respectively.   
At present, the biological significance of this interaction remains unknown, which 
presumably affects the complement activation and C5a generation.  
 103 
 
 
 
Figure 32 Biacore analysis of the 
interactions between C5 and the 
recombinant Bbp or SdrE 
proteins. 
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